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ABSTRACT 
The atypical antipsychotic drug (APD) clozapine is the most efficacious APD in treatment-resistant 
schizophrenia including negative symptoms and cognitive impairment, and still lacks extrapyramidal 
side effects (EPS). Clozapine, which also possesses an antidepressant effect and can be used as 
monotherapy in bipolar disorder, has a broad receptor binding profile with higher affinity for the α2-
adrenoceptor and several serotonergic receptors than D2 receptor, enhances dopamine output in the 
medial prefrontal cortex (mPFC) and facilitates glutamatergic NMDA receptor-mediated transmission 
in pyramidal cells in the same brain region. These effects may clearly contribute to its superior clinical 
efficacy, although haematological side effects limit its use. The atypical APD olanzapine lacks e.g. the 
high affinity to the α2-adrenoceptor, as well as the high efficacy of clozapine, and generates dose 
dependent EPS. Previous studies show that addition of the selective α2-adrenoceptor antagonist 
idazoxan to olanzapine may enhance its antipsychotic-like effect and increase dopamine output in the 
mPFC, effects that might also be achieved by inhibition of the norepinephrine transporter (NET). In 
the present study we investigated whether adjunct treatment with reboxetine, a selective NET inhibitor 
used for the treatment of depression, might generate another means to augment the antipsychotic-like 
effect of olanzapine and, in principle, provide a somewhat more clozapine-like effect. Addition of 
reboxetine potentiated the antipsychotic-like effect of low doses of olanzapine, without increasing EPS 
liability. This combined treatment also preferentially enhanced cortical dopamine output and NMDA 
receptor-mediated currents in pyramidal cells of the mPFC in slice preparations. The results propose 
that adjunct NET inhibition by reboxetine may be used to augment the antipsychotic effect of low 
doses of olanzapine in schizophrenia and improve the effect on negative symptoms and cognitive 
impairments.  We continued to experimentally investigate whether NET inhibition by norquetiapine, 
an active metabolite of quetiapine in humans but not in rodents, and a potent NET inhibitor, may 
contribute to the overall effects of quetiapine in patients. To this end we studied the effects of 
reboxetine added to quetiapine in rodents and found an augmented antipsychotic-like effect and a 
selectively enhanced dopamine output in the mPFC. As the increased extracellular dopamine levels in 
the mPFC were accompanied by a decrease in DOPAC levels, the enhanced extracellular dopamine 
levels should represent a consequence of NET inhibition. Although high concentrations of quetiapine 
alone facilitated NMDA-induced currents in the mPFC, concomitant NET inhibition was found to 
generate the same effect at a low, subeffective concentration of quetiapine, being mediated via the 
dopamine D1 receptor.  Consequently, NET inhibition generated by the active metabolite 
norquetiapine in patients should, in principle, contribute to the clinical antipsychotic effect of 
quetiapine, which is obtained at low D2 receptor occupancy, and furthermore serve to improve 
depressive symptoms as well as cognitive impairments. Low to moderate doses of atypical APDs 
added to selective serotonin reuptake inhibitors (SSRIs) have been found to augment the 
antidepressant effect with a rapid onset compared to SSRIs alone. Our data show that addition of low 
doses of the novel atypical APD asenapine to the SSRI escitalopram enhances the output of 
monoamines in the mPFC and also facilitates not only NMDA, but also AMPA receptor-mediated 
transmission in pyramidal cells of the mPFC, both effects being mediated via activation of the 
dopamine D1 receptor. A similar effect was also obtained by a combination of low concentrations of 
olanzapine and the SSRI fluoxetine. Significantly, a systemic ketamine injection 24 hours prior to the 
electrophysiological experiments, which previously has been found to produce a rapid and potent 
antidepressant-like effect in rodents, significantly potentiated AMPA receptor-mediated transmission 
in the mPFC in our study. Consequently, our data propose that asenapine may be clinically used as 
adjunct to SSRIs in treatment-resistant depression to augment and hasten the clinical response. Overall 
our data thus propose that the relatively rapid onset of the augmented antidepressant effect of 
combined antipsychotic and antidepressant drug treatments may be related to an enhanced AMPA 
receptor-mediated transmission in the PFC, in analogy with the effects of ketamine. In summary, our 
experimental results suggest that an enhanced efficacy in both schizophrenia and depression may be 
achieved by combined administration of atypical APDs and antidepressant drugs.
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1. Introduction 
Mental illness has been defined as “health conditions that are characterized by 
alterations in thinking, mood, or behavior (or some combination thereof) associated 
with distress and/or impaired functioning” (HHS, 1999). In a study investigating the 
global burden of disease, psychiatric disorders occupied five places on the top-ten list of 
the leading causes of disability in the world, when calculated as years lived with a 
disability (Lopez and Murray, 1998). In addition to immense personal suffering for the 
afflicted and his next of kin, mental illness poses an enormous cost to society with 
regards to direct and indirect medical cost (Gustavsson et al., 2011, Wittchen et al., 
2011).  
The discovery of several new drugs (e.g. chlorpromazine, lithium and imipramine) 
revolutionized psychiatric care during the latter half of the 20
th
 century and changed the 
life for large patient groups that previously had been without rational treatments and 
been confined to hospitalization. Even though many drugs have been developed since 
then, the efficacy and side effect profile of the drugs available today are by no means 
optimal. 
Approximately one third of patients suffering from depression achieve remission with 
selective serotonin reuptake-inhibitors, the most prescribed antidepressant drugs 
(Trivedi et al., 2006). Moreover, a recent Swedish study showed that, although there are 
a number of effective antipsychotic drugs (APDs) available, schizophrenia is still so 
debilitating that less than one in fourteen schizophrenic patients are employed, suicide 
rates are increased ten-fold and schizophrenic patients are estimated to die 12 to 15 
years earlier than the rest of the population as a consequence of their disease (Crump et 
al., 2013). Thus, improved treatments for these diseases are urgently needed. In the 
present thesis, using preclinical methodologies, I have investigated augmentation 
strategies to improve the treatment of schizophrenia and mood disorders by combining 
conventional antidepressant drugs and APDs. 
1.1. Neurotransmitter systems 
1.1.1. The dopamine system 
In 1957, Montagu claimed to have identified dopamine in brain tissue from several 
species (Montagu, 1957). However, it was Carlsson and co-workers who originally 
discovered that dopamine has a physiological function as a neurotransmitter in its own 
right, not just serving as a precursor in the synthesis of noradrenaline (Carlsson et al., 
1957, Carlsson et al., 1958, Carlsson, 1959). Since its discovery, dopamine has been 
found to be critically involved with a multitude of complex behaviors such as reward, 
cognition, salience and movement control. Aberrant dopaminergic transmission is 
thought to be involved in several central nervous system (CNS) disorders, accordingly, 
drugs affecting dopaminergic transmission are used in e.g. schizophrenia, Parkinson’s 
disease and mood disorders. 
Carl Björkholm 
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1.1.2. The dopamine pathways 
In the CNS, the dopaminergic system can be divided into four distinct pathways; 
namely the nigrostriatal, the mesocortical, the mesolimbic and the tuberoinfundibular 
pathway (Dalström and Fuxe, 1964, Ungerstedt, 1971, Moore and Bloom, 1978; figures 
1, 2). In the nigrostriatal pathway, the cell bodies are located in the substantia nigra 
(SN; A9), and project predominantly to the dorsal striatum (STR), i.e. caudate and 
putamen, where they form extensive axonal arborizations which can measure up to 500 
mm in length (Matsuda et al., 2009). The nigrostiatal pathway is involved in movement 
control, and Parkinson’s disease is largely caused by cell death in this pathway 
(Hornykiewicz, 1962). Moreover, massive blockade of D2 receptors in the dorsal 
striatum may induce extrapyramidal side effects, (EPS) such as Parkinsonism, which is 
a common side effect of most, but not all APDs, especially in higher doses (see 3.4).  
Figure 1. Dopaminergic 
pathways in the human 
brain. AM: amygdala; Hip: 
hippocampus; Hyp: 
hypothalamus; NAC: 
Nucleus accumbens; P: 
pituitary gland; PFC: 
prefrontal cortex; SN: 
substantia nigra; Th: 
Thalamus; VTA: ventral 
tegmental area. Modified 
from (Rang et al., 1999). 
 
 
Dopamine cells that originate in the ventral tegmental area (VTA; A10) constitute the 
other main dopaminergic pathway, the mesocorticolimbic pathway. Depending on 
where the dopamine neurons in the VTA project, the mesocorticolimbic pathway can be 
further divided into the mesocortical part (projecting to the prefrontal cortex [PFC]) and 
the mesolimbic part projecting to subcortical brain regions e.g. the ventral STR (i.e. the 
nucleus accumbens [NAc]), amygdala and the hippocampus. The pituitary gland and the 
median eminence receive dopaminergic input from the arcuate nucleus in the 
hypothalamus and this pathway constitute the tuberoinfundibular system which acts 
inhibitory on the prolactin synthesis and secretion, via activation of D2 receptors 
(Fitzgerald and Dinan, 2008). Thus, blockade of D2 receptors, by APDs (especially 
typical APDs) may increase the secretion of prolactin, causing side effects such as 
galactorrhea. 
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Figure 2. Schematic drawing showing monoaminergic pathways innervating the prefrontal 
cortex (PFC) on coronal sections of rat brain. The noradrenergic pathway projects from the 
locus coeruleus (LC), the serotonergic pathway from the dorsal and median raphe (DR, MR) 
and the dopaminergic pathway from ventral tegmental area (VTA). NAC: Nucleus accumbens; 
SN: Substantia nigra. Modified from (Fuster, 1997). 
1.1.3. Dopamine synthesis and elimination 
Dopamine is synthesized from the amino acid tyrosine, which is actively transported 
over the blood brain barrier into the brain (Brunton et al., 2011). Tyrosine is first 
converted to L-dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase 
before L-DOPA is converted into dopamine by the enzyme dopa-decarboxylase (figure 
3). Dopamine is transported into synaptic vesicles by the vesicular monoamine 
transporter2 (VMAT2), which is located in the vesicular membrane. The drug reserpine 
inhibits VMAT2 and thereby inhibits the transport of monoamines into vesicles, which 
depletes the terminals of monoamines. Dopamine is released into the synaptic cleft 
when vesicles are fused with the cell membrane (exocytosis) via a Ca
2+
-dependent 
mechanism initiated by nerve impulses. Once released into the synaptic cleft, the main 
elimination route of dopamine is reuptake back into the dopaminergic terminal by the 
dopamine transporter (DAT). Blockade of the DAT causes a large increase in 
extracellular dopamine levels and represents a major mechanism of action of several 
drugs such as cocaine and bupropion. When dopamine is transported back into the 
terminal, it can either be packed into vesicles and reused or metabolized to 
dihydroxyphenyl acetic acid (DOPAC) by the enzymes monoamine oxidase (MAO) and 
aldehyde dehydrogenase. In the extracellular space, dopamine can also be metabolized 
by catechol-O-methyl transferase (COMT) into 3-metoxytyramine (3-MT). 3-MT and 
DOPAC may also be further metabolized into homovanillic acid (HVA), by MAO and 
COMT respectively. There are two isoforms of the MAO enzyme, MAO-A and MAO-
B. MAO-A has higher affinity for serotonin, whereas both dopamine and noradrenaline 
show equal affinity for these enzymes (Waldmeier, 1987, Berry et al., 1994). MAO-A 
inhibitors are used as antidepressant drugs, whereas MAO-B inhibitors are 
preferentially used in the treatment of Parkinson’s disease. 
Carl Björkholm 
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1.1.4. Dopamine receptors  
The dopamine receptors are divided into two families depending on their structural, 
pharmacological and signaling properties (see Beaulieu and Gainetdinov, 2011, Tritsch 
and Sabatini, 2012, and references therein). The D1– like family consists of D1 and D5 
receptors and the D2- like family consists of D2, D3 and D4 receptors. Pharmacological 
agents can distinguish between the two families, but usually possess less specificity 
within each family. In general, stimulation of D1-like and D2-like receptors exert 
opposite effects by activation of different second messenger pathways. Dopamine has 
been found to possess a higher affinity for the D2-like receptors than the D1-like 
receptors.  
Figure 3. Schematic drawing 
illustrating a dopaminergic nerve 
terminal. 3-MT: 3-metoxytyramine; 
AD: aldehyde dehydrogenase; APDs: 
antipsychotic drugs; COMT: 
catecholamine-O-methyl transferase; 
DA: dopamine; MAO: monoamine 
oxidase. Modified from (Cooper et al., 
2003). 
 
 
 
 
 
Binding of dopamine to the D1 receptor activates Gαs or Gα/olf, which are positively 
coupled to adenylyl cyclase and thereby increases cyclic adenosine monophosphate 
(cAMP) production (Brunton et al., 2011). Increased levels of cAMP may subsequently 
activate protein kinase A (PKA). D1 receptor activation is also suggested to couple to Gq 
and enhance the production of inositol triphosphate (IP3) and diacylglycerol (DAG). 
PKA mediates most of the effects of D1 receptor stimulation, and PKA may in turn 
regulate the function of several different cellular substrates, such as voltage gated ion 
channels, ionotropic glutamate receptors, γ-aminobutyric acid (GABA)-ergic receptors 
and transcription factors. PKA may also activate the dopamine and cAMP-regulated 
phosphoprotein of 32-kDa (DARPP-32). This effect on DARPP-32 can be inhibited by 
activation of D2 receptors. D2 receptor activation inhibits adenylyl cyclase activation but 
may also affect intracellular Ca
2+
 levels and voltage-gated ion channels independently 
of cAMP/PKA inhibition. D2 receptors are expressed presynaptically as well as 
postsynaptically. D2 receptors located on the soma and dendrites of dopaminergic cells 
act as autoreceptors, decreasing firing frequency (see below) whereas D2 receptors 
located on nerve terminals reduce dopamine synthesis and release. D2 receptors exist in 
two splice variants D2S (short) and D2L (long). D2L is predominantly located 
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postsynaptically whereas D2S is predominantly expressed presynaptically (Brunton et 
al., 2011).  
Dopamine receptors are expressed in regions that receive dopaminergic innervations. 
The most commonly expressed receptor subtypes are the D1 and the D2 receptors, with 
the D1 being the most widely distributed and abundant. In subcortical areas, the 
expression of D1 and D2 are approximately equal whereas in the cortex, the D1 type 
outnumbers the D2. Dopamine receptors (D1 and D2 subtypes) are expressed on medium 
spiny neurons as well as interneurons in the STR and on as on cortical pyramidal cells, 
interneurons and glial cells (Tritsch and Sabatini, 2012). The D3 receptor shows a lower 
expression than the D2 receptor and is predominantly found in limbic regions. The D4 
and D5 receptors are expressed in e.g. cortical regions but also limbic areas (Tritsch and 
Sabatini, 2012).  
1.1.5. Regulation of dopamine cell activity 
Midbrain dopamine cells (i.e. located in SN or VTA) essentially display two modes of 
function, single spike firing and burst firing i.e. short bursts of action potentials with 
high frequency (Bunney et al., 1973, Grace and Bunney, 1983). Burst firing is 
associated with a larger release of dopamine in both cortical and subcortical areas 
(Gonon, 1988, Bean and Roth, 1991, Chergui et al., 1996) and may be especially 
important for signaling reward or salience (Schultz, 2010). Single spike firing on the 
other hand, may provide a basal tonic stimulation of dopaminergic receptors which is 
important for e.g. motor activity (Schultz, 2007). 
Activation of somatodendritic D2 receptors on midbrain dopamine cells hyperpolarizes 
the neurons and reduces their firing rate by enhancing K
+
 conductance (Bunney et al., 
1973, Lacey et al., 1987). However, the mesocortical dopamine cells are not regulated 
by autoreceptors (Chiodo et al., 1984). The cortically projecting dopamine cells also 
respond differently to e.g. N-methyl-D-aspartate (NMDA) receptor antagonists than the 
mesolimbic dopamine neurons (see e.g. Murase et al., 1993b), have higher firing 
frequencies and fire a larger proportion of spikes in bursts compared with dopamine 
cells in the mesolimbic or nigrostriatal pathways. In addition, mesolimbic dopamine 
release appears to be subjected to negative feed-back control by dopamine in the mPFC 
(Pycock et al., 1980, Deutch et al., 1990). Thus, mesocortical and mesolimbic dopamine 
cells are differentially regulated in several ways. Moreover, the midbrain dopamine 
cells are negatively modulated by GABAergic interneurons as well as GABAergic 
feedback loops originating in brain regions innervated by dopamine such as the STR 
and the NAc (Fonnum et al., 1978, Walaas and Fonnum, 1980).  
Dopamine cells receive excitatory input from the PFC but also from e.g. the 
subthalamic nucleus (Grace and Bunney, 1985, Svensson and Tung, 1989, Chergui et 
al., 1994). This is indicated by experiments showing that inactivation of the mPFC 
reduces burst firing, whereas activation of the mPFC increases the proportion of spikes 
fired in bursts in dopamine cells in the VTA (Gariano and Groves, 1988, Svensson and 
Tung, 1989, Murase et al., 1993a). The dopamine cells in the VTA also receive a 
Carl Björkholm 
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noradrenergic input from locus coeruleus (LC), neurons which may enhance burst 
activity via activation of excitatory α1-adrenoceptors on the dopaminergic cell bodies 
(Grenhoff et al., 1993, Grenhoff and Svensson, 1993). The VTA receives serotonergic 
afferents from the raphe nuclei and although the modulation of dopamine firing in the 
VTA is complex, the main effect seems to be inhibitory (Di Giovanni et al., 2008). 
1.1.6. Regulation of dopamine in the cortex 
The expression of DAT is scarce in the PFC, in contrast to the abundant DAT 
expression in other dopaminergic terminal areas, such as the STR (Sesack et al., 1998). 
As a consequence, prefrontal dopamine is essentially inactivated by the norepinephrine 
transporter (NET) located in noradrenergic nerve terminals (Carboni et al., 1990, Pozzi 
et al., 1994). As a result, NET-inhibitors increase both dopamine and noradrenaline 
levels in the mPFC to a similar extent, but does not affect dopamine levels in NAc or 
STR where dopamine is cleared by the DAT (Bymaster et al., 2002). Furthermore, 
blockade of the α2-adrenoceptor in the mPFC increases the extracellular levels of 
dopamine (Hertel et al., 1999b). In fact, lesion and pharmacological studies indicate that 
dopamine may be co-released with noradrenaline from noradrenaline terminals in the 
mPFC (Devoto et al., 2001, Devoto and Flore, 2006, Masana et al., 2011).  
1.2. The glutamate system 
Glutamate is the main excitatory neurotransmitter in the CNS and is found in high 
concentrations throughout the brain. It is estimated that approximately 80 % of all 
neurons and 85% of all synapses in the human neocortex are glutamatergic (Douglas 
and Martin, 2007). Given the almost ubiquitous nature of glutamate, it is involved in 
almost all processes in the brain, in one way or the other. The majority of the 
glutamatergic projections is descending and project from the cortex to subcortical 
regions, but may also project within the cortex (i.e. cortico-cortical projections). In the 
nerve terminals, glutamate can be synthesized from glucose, via the Krebs cycle, or 
from glutamine, which is synthesized in glia, and converted to glutamate by 
glutaminase. Inactivation of released glutamate is accomplished by reuptake into 
neurons or glia. In glia, glutamate is metabolized into glutamine by glutamine 
synthease. Glutamine is subsequently transported to neighboring neurons where it is 
converted to glutamate and subsequently reused. Glutamate receptors include ionotropic 
receptors, i.e. NMDA, AMPA and kainate receptors, as well as metabotropic glutamate 
receptors (mGluR 1-7). Glutamate receptors of all types have been found to be located 
both pre- and postsynaptically (Pinheiro and Mulle, 2008). 
1.2.1. NMDA-receptors 
The NMDA receptor is a ligand-gated voltage-dependent ionotropic receptor that is 
widely expressed in the CNS (figure 4). NMDA receptors have slow 
activation/deactivation kinetics and are highly permeable to Ca
2+
 as well as Na
+
 and K
+
 
(see Cull-Candy et al., 2001 and references therein). NMDA receptors are essential for 
neuronal development, learning and neural plasticity as well as neural cell death.  
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Figure 4. Schematic drawing of glutamatergic ionotropic receptors. Co-agonist i.e. glycine or 
D-serine; Glu: glutamate; APV: D(−)-2-Amino-5-phosphonopentanoic acid, a competitive 
NMDA receptor antagonist; CNQX: 6-Cyano-7-nitroquinoxaline-2,3-dione, a AMPA/ Kainate 
receptor antagonist. Modified from (Kandel et al., 1991). 
The activity of the NMDA receptor is regulated by several different mechanisms. In 
addition to glutamate, NMDA receptor activation also requires binding of a co-agonist 
(glycine or D-serine) controlling the number of NMDA receptors that can be activated 
by released glutamate (Johnson and Ascher, 1987, Mothet et al., 2000, Oliet and 
Mothet, 2009). Glycine levels are regulated by glycine transporters which are located on 
glial cells and glutamatergic neurons close to NMDA receptor synapses (Cubelos et al., 
2005, Eulenburg et al., 2005). In addition, NMDA receptor ion-channels are blocked by 
Mg
2+
 ions at resting membrane potentials and in order for the NMDA receptor to be 
activated, the membrane potential must be depolarized (Cull-Candy et al., 2001). In the 
postsynaptic density, NMDA receptors may associate with scaffolding, anchoring and 
signaling proteins (Cull-Candy et al., 2001).  
There is considerable heterogeneity among the NMDA receptors, depending on their 
subunit composition (Cull-Candy et al., 2001). There are eight different splice variants 
of the NR1 subunit, four different NR2 subunits and two NR3 subunits. The NMDA 
receptor is considered to be a tetramer, the most common consisting of two NR1 
subunits and two NR2 subunits, which can be of different splice variants. However, the 
NMDA receptor may also contain NR3 subunits. The subunit composition is important 
as it determines the pharmacological and biophysical properties of the NMDA receptor. 
NR2 subunits bind glutamate and contain the modulatory site, binding Zn
2+
, whereas the 
NR1 and NR3 subunits contain the co-agonist site. Phencyclidine (PCP), ketamine and 
MK-801 bind to the pore of the ion-channel and thereby block the transmission. 
1.2.2. AMPA and kainate receptors 
The AMPA and kainate receptors are ionotropic receptors, which are responsible for the 
major part of the fast excitatory transmission in the CNS. The AMPA receptors are co-
localized with NMDA receptors. Activation of AMPA receptors induces an influx of 
Na
+
 increasing the membrane potential, which is required to release the Mg
2+
 blockade 
of the NMDA receptor (see above). Activation of NMDA receptors may regulate the 
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number of AMPA receptors in the synapse trough Ca
2+
 influx and triggering of 
intracellular cascades, thus regulating the synaptic strength (i.e. long term depression or 
long term potentiation; Malinow and Malenka, 2002, Citri and Malenka, 2008). 
Regulation of synaptic strength is thought to be involved in learning and memory.  
The AMPA receptors are composed of four subunits (GluR1 to 4), which each contains 
a glutamate binding-site (Rosenmund et al., 1998). AMPA receptors may be heteromers 
as well as homomers (Wenthold et al., 1996). Most AMPA receptors are Na
+
 and K
+ 
permeable to but may also be permeable to Ca
2+
 if the receptor lacks the GluR2 subunit. 
The kainate receptors form homo- and heterotetramers from the subunits GluR5-7 and 
KA1 and 2. The kainate receptors are distributed throughout the brain but are less 
abundant than the AMPA receptors (Pinheiro and Mulle, 2006). 
1.2.3. Metabotropic glutamate receptors  
There are eight types of metabotropic glutamate receptors (mGluRs) divided into three 
groups (see Nicoletti et al., 2011, and references therein). Group I includes GluR1 and 
5, group II includes mGluR 2 and 3, and subsequently, group III includes mGluRs 4, 6, 
7 and 8. mGluRs are expressed on neurons as well as on microglia and astrocytes and 
are widely expressed throughout the brain. The mGluRs are involved in pre- and 
postsynaptic regulation of synaptic transmission and are considered as interesting drug 
targets for the treatment of a number of neuropsychiatric disorders, such as depression, 
anxiety and schizophrenia. For example, mGluR2/3 agonists, which attenuate glutamate 
release, have been developed for schizophrenia and initially showed encouraging results 
(Patil et al., 2007). However, a subsequent trial could not confirm the initial finding 
(Kinon et al., 2011) and thus the effectiveness of mGlu2/3 as a target for schizophrenia 
remains to be conclusively determined. 
1.2.4. Dopamine D1 receptor and NMDA receptor interactions in the PFC 
Several lines of evidence support the functional as well as physical interaction between 
the dopamine D1 and the NMDA receptor. In fact, optimal interaction between the D1 
receptor and the NMDA receptor in the PFC has been proposed as a crucial mechanism 
for cognitive function (Castner and Williams, 2007).  
Dopamine projections to the mPFC terminate mainly in deep cortical layers (layer V 
and VI) and pyramidal cells in layer V receive both dopaminergic and glutamatergic 
input from the VTA and from the thalamus, respectively (Kuroda et al., 1996). D1 
receptors and NMDA receptors co-localize on pyramidal cells, as well as on 
interneurons in the rat mPFC (Kruse et al., 2009). Dopamine D1 receptor activation has 
been found to facilitate NMDA-induced responses and to potentiate excitatory 
postsynaptic potentials (EPSPs) in layer V pyramidal cells of the rat mPFC (Seamans et 
al., 2001, Tseng and O'Donnell, 2004), whereas α- or β-adrenoceptors do not seem to 
affect NMDA-induced currents (Wirkner et al., 2004). In contrast to the well established 
interaction between the D1 and NMDA receptors, interactions between D1 and AMPA 
receptors remain to be clarified. 
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1.3. The serotonin system 
Evolutionary, serotonin is thought to be one of the oldest neurotransmitters and is found 
to in the CNS as well as in the peripheral nervous system and in various non-neural 
tissues. The distribution of serotonin is widespread in the brain (figure 2 and 5) and 
serotonin modulates a number of important functions including sleep, mood, aggression, 
cognition, temperature and feeding. Accordingly, the cerebral serotonin system is a 
target for the treatment of several psychiatric disorders, such as depression and anxiety. 
Figure 5. Schematic drawing illustrating 
the serotonergic pathways in the human 
brain. AM: amygdala; C: cerebellum; 
Hip: hippocampus; Hyp: hypothalamus; 
Str: striatum; Sep: Septum; Th: Thamalus. 
Modified from (Rang et al., 1999). 
 
 
 
 
 
1.3.1. Serotonins synthesis and elimination 
Serotonin is synthesized in serotonergic neurons from tryptophan which is converted 
into 5-hydroxytryptamine (5-HT; i.e. serotonin), via 5-hydroxytrypophan by the 
enzymes tryptophan hydroxylase and amino acid decarboxylase, respectively (Figure 6.) 
(Brunton et al., 2011). In the nerve terminal, serotonin is packed into vesicles and 
released into the synaptic cleft by exocytosis through a nerve impulse initiated Ca
2+
-
dependent mechanism. The main route of elimination is reuptake by the serotonin 
transporter (SERT). Serotonin is metabolized by MAO and aldehyde dehydrogenase 
into its main metabolite 5-hydroxyindole acetic acid (5-HIAA).  
Figure 6. Schematic drawing illustrating a 
serotonergic nerve terminal. 5-HT: 5-
hydroxytryptamine i.e. serotonin; MAO: 
monoamine oxidase. Modified from (Cooper 
et al., 2003). 
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1.3.2. Serotonin projections 
The serotonergic pathways in the CNS project from the raphe nuclei located in the brain 
stem (Dahlström and Fuxe, 1964), to most regions of the brain. From the medial and 
dorsal raphe, serotonergic cells project rostrally to e.g. the thalamus, hypothalamus, 
striatum, amygdala, hippocampus and the cortex via the medial forebrain bundle (figure 
2 and 6) whereas from caudal parts of the raphe nuclei, serotonergic cells project to the 
cerebellum and the spinal cord.  
1.3.3. Serotonin receptors 
There are 14 types of serotonergic receptors, 5-HT1-7 (with subgroups), all of which are 
G-protein coupled except for the 5-HT3 receptor, which is an excitatory ligand-gated ion 
channel (Hannon and Hoyer, 2008). There are several different subgroups of the 
serotonin receptors for example 5-HT1A, B, D, E, F and 5-HT2A/B/C. The 5-HT1A and 5-
HT2A/C receptors are involved in the mechanism of action of many APDs see e.g. 
(Ichikawa et al., 2001). 5-HT1A receptors are mostly linked to Gi and may hyperpolarize 
the cell membrane and reduce adenylate cylase. 5-HT1A receptors are expressed in e.g. 
the hippocampus and in cortical areas as well as on cell bodies in the raphe nuclei, 
where it acts as an autoreceptor. 5-HT2 receptors are preferentially Gq coupled and 
increases IP3 and PKC, which subsequently enhances the intracellular Ca
2+
 
concentration. 5-HT2A receptors are expressed on e.g. cortical pyramidal cells and 
interneurons as well as in the brain stem, limbic areas and in the basal ganglia. 5-HT2B 
receptors are expressed in lower number than the 5-HT2A and 5-HT2C, and confined to 
discrete regions e.g. the medial amygdala where 5-HT2B activation induce anxiolytic 
effects in rodents. 5-HT2C receptors are expressed in limbic structures and in substantia 
nigra as well as in some cortical structures.  
 
1.4. The noradrenaline system 
Noradrenaline was first identified as a CNS neurotransmitter in the 1950’s (Vogt, 
1954). Noradrenaline has been found to modulate the activity of neurons, more 
specifically noradrenaline may function to enhance signal to noise ratio (i.e. enhance 
activity in active cells and depress activity in less active cells) in target areas. 
Noradrenaline transmission is suggested to be involved in e.g. attention, behavioral 
reorientation and is thought to function as a significance enhancer (Aston-Jones et al., 
1999, Arnsten and Li, 2005). The cerebral noradrenergic transmission represents a 
target for a number of different psychoactive drugs, including antidepressants, 
antipsychotics and drugs used in the treatment of attention deficit hyperactive disorder 
(ADHD). 
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Figure 7. Schematic drawing 
illustrating the noradrenergic 
pathways in the human brain. AM: 
amygdala; C: cerebellum Hip: 
hippocampus; Hyp: hypothalamus 
;LC: locus coeruleus; LTG: lateral 
tegmental group; Str: striatum; sep: 
septum; Th: thamalus. Modified 
from (Rang et al., 1999). 
 
 
 
1.4.1. Noradrenaline synthesis and elimination 
Noradrenaline is synthesized from dopamine in noradrenergic terminals by the enzyme 
dopamine β-hydroxylase (Brunton et al., 2011). Dopamine β-hydroxylase is bound to 
the vesicular membrane and, noradrenaline synthesis occurs inside the vesicles (figure 
8). Noradrenaline is released via a nerve impulse-dependent mechanism and is cleared 
from the synaptic cleft by the NET. Noradrenaline is metabolized to its major 
metabolite 3-methoxy-4-hydroxyl-phentylenglycol (MHPG) by COMT and MAO.  
1.4.2. Noradrenaline projections 
Noradrenergic cell bodies are located in several clusters in the brain stem and can be 
divided into two subgroups, the LC and the lateral tegmental nuclei (Dahlström and 
Fuxe, 1964; figures 2 and 7). The LC projects to most of the cerebral cortex, as well as 
to e.g. the cerebellum, hippocampus and the amygdala. The lateral tegmental nuclei 
project mainly to other brain regions such as the brain stem, the hypothalamus, parts of 
the amygdala and the spinal cord.  
Figure 8. Schematic drawing of 
a noradrenergic nerve terminal. 
DA; dopamine; MHPG: 3-
methoxy-4-hyroxyl- 
phentylenglycol ; COMT: 
catecholamine-O-transferase; 
MAO: monoamine oxidase; 
NA: noradrenaline NM; 
normetanephrine. Modified 
from (Cooper et al., 2003). 
 
 
 
Carl Björkholm 
12 
 
1.4.3. Noradrenaline receptors 
There are two types of noradrenaline receptors α- and β-adrenoceptors (Bylund et al., 
1994, Civantos Calzada and Aleixandre de Artinano, 2001). The α-adrenoceptors are 
divided into α1- and α2- adrenoceptors which are both widely distributed in the brain 
(Nicholas et al., 1996). The α1 receptors are positively coupled to Gq and thus stimulates 
phospholipase C and increases IP3 and DAG. There are three subclasses of the α1 -
adrenoceptors, the α1A/B/D. α1-receptors are predominantly located on postsynaptic 
neurons e.g. on pyramidal cells of the mPFC where they co-localize with 5-HT2A 
receptors and increase the excitation of the cells (Santana et al., 2013). Presynaptically 
located α1-adrenoceptors have been found in e.g. NAc, where they are thought to 
regulate dopamine release (Mitrano et al., 2012). α2-adrenoceptors are negatively 
coupled to cAMP production and thereby act inhibitory. The inhibitory function of 
presynaptic α2-adrenoceptors on transmitter release was first demonstrated on central 
noradrenaline neurons by Andén and colleagues (Anden et al., 1970b) and, 
independently, on peripheral sympathetic nerves by Langer (Langer, 1970). Now it is 
known that α2-adrenoceptors act as hetero- and autoreceptors, regulating noradrenergic 
as well as serotonergic and dopaminergic transmission (Svensson et al., 1975, Gobert et 
al., 1998, Devoto et al., 2001). There are three subclasses of β-adrenoceptors, β1/2/3, but 
only β1/2 are expressed in the CNS (Nicholas et al., 1996). The β1/2-receptors are 
positively coupled to Gs activating adenylyl cyclase. β-adrenoceptors have been found 
to modulate neurotransmission in the mPFC and may be involved in for example 
memory retrieval (Ji et al., 2008, Reyes-Lopez et al., 2010). 
1.5. Prefrontal cortex 
The human PFC has been divided into three anatomically different regions the lateral, 
medial and orbital regions (Fuster, 2001). The PFC is involved in emotional behavior 
and cognitive processes that includes behavior, speech and reasoning, planning and 
executive function. In the PFC, information from external sources (sensory information) 
and internal sources (memories, mood) is integrated and an appropriate response is 
selected. The human PFC is not fully mature until early adulthood (Fuster, 2001). 
Patients who sustained lesions in the dorsolateral PFC (dlPFC) may display cognitive 
deficits such as problems with generating coherent speech, memory retrieval as well as 
working memory and attention deficits (Stuss and Levine, 2002). The critical 
importance of the PFC for working memory is supported by a plethora of animal 
studies. Hypofunction of the PFC is well established in schizophrenia, and is thought to 
contribute to the negative symptoms and cognitive deficits (c.f. 1.7). Recent studies, 
using imaging techniques, showed that poor activation of the dlPFC corresponded to 
poor cognitive performance in schizophrenic patients, but not in patients suffering from 
cognitive decline caused by ageing (Dreher et al., 2012). This indicates that the dlPFC 
dysfunction is a core deficit in schizophrenia, but not for poor cognition per se. The 
dlPFC is also implicated in emotional processing and impaired function of the dlPFC 
has been proposed also in depression (Savitz and Drevets, 2009). For example, 
hypometabolism and even reduced grey matter in the dlPFC has been observed in 
MDD.  
                                                                                                                                                      Introduction                                                                                                                                                               
13 
 
The rat cerebral cortex is approximately 1000 times smaller than that of a human cortex, 
making a direct translation based on anatomy alone impossible (c.f. Uylings et al., 
2003). The region in rat cortex that best corresponds to the human dlPFC is the rat 
medial PFC (mPFC; Ongur and Price, 2000, Uylings et al., 2003). This notion is based 
on the fact that the rat mPFC, in similarity to the human dlPFC, forms extensive 
reciprocal projections from e.g. the mediodorsal thalamus, receives similar 
neurotransmitter input (e.g. noradrenaline from the LC, serotonin from the DRN, 
dopamine from the VTA) and expresses similar receptors as the human dlPFC. In 
addition, analogous behaviors are mediated via these areas in humans and rats, 
respectively, such as attention, working memory and social interaction. The rat mPFC is 
considered to consist of four regions, medial (frontal) agranular, anterior cingulate 
cortex, prelimbic cortex and infralimbic cortex (Ongur and Price, 2000, Uylings et al., 
2003, Hoover and Vertes, 2007). The medial agranular and the anterior cingulate cortex 
receive afferents from large areas of the cortex and thalamic nuclei whereas the 
prelimbic and infralimbic corex generally receive less cortical afferents and instead 
more limbic afferents (Hoover and Vertes, 2007).  
1.6. Nucleus Accumbens 
The NAc is a forebrain structure that makes up most of the ventral striatum. The main 
cell type of the NAc is the GABAergic medium spiny neurons, which express D1 or D2 
receptors (Tritsch and Sabatini, 2012). The NAc receives dopaminergic input from the 
VTA, via the mesolimbic dopamine projection, and glutamatergic input from limbic 
regions as well as the mPFC. The NAc has been suggested to act as an interface 
between the motor system and the limbic system, in which motivation is translated into 
action (Mogenson et al., 1980). Thus, the NAc is important for a number of processes 
including reward, reinforcement, hedonia and motivation. The NAc can be subdivided 
into the shell and core compartments. The shell mainly receives input from the 
infralimbic subdivision of the mPFC and the core from the prelimbic subdivision. The 
core region is functionally related to dorsal striatum and is thought to be involved in 
motor function whereas the shell region is thought to be more associated with the limbic 
system and to be involved in motivational and emotional processes (Deutch, 1993). 
Studies show that clozapine and other atypical APDs preferentially increase dopamine 
release in the shell region, whereas the typical APD haloperidol induces dopamine 
release preferentially in the core (Marcus et al., 2000, Marcus et al., 2002) 
1.7. Schizophrenia  
Schizophrenia is a severe psychiatric disorder which affects almost all domains of the 
personality as well as the mental capacity and thereby severely affects the ability of an 
individual to function in society. The severity of the symptoms and the fact that the first 
symptoms usually appear in the late teens or early adulthood, i.e. periods important for 
e.g. education, building a career and family, contribute to the fact that the disease 
usually is associated with short education, low rates of employment and marriage, as 
well as low income (Crump et al., 2013).  
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The estimated lifetime prevalence of schizophrenia is approximately 0.5 to 1% (Regier 
et al., 1988, Carpenter and Buchanan, 1994, Goldner et al., 2002). Most patients 
experience their first psychotic symptoms in adolescence or early adulthood (an der 
Heiden and Hafner, 2000). In a majority of patients, schizophrenia develops into a 
chronic disease with poor outcome (Carone et al., 1991, Bromet and Fennig, 1999). As 
a consequence, schizophrenic patients have a reduced life expectancy of approximately 
12 to 15 years mainly due somatic diseases (e.g. ischemic heart disease and cancer) but 
in addition, schizophrenia is associated with high risk of suicide and other causes of 
unnatural death (Casey et al., 2011, Crump et al., 2013). Even though some APDs are 
associated with severe side effects such as the metabolic syndrome, they have still been 
found to significantly reduce mortality in schizophrenia (Tiihonen et al., 2009, Crump et 
al., 2013). In addition, co-morbid diseases such as drug abuse are common and may 
significantly worsen the prognosis of schizophrenia (c.f. Krystal et al., 1999).  
1.7.1 Symptoms of schizophrenia  
The diverse symptoms of schizophrenia were first described as one disease under the 
name dementia praecox by the German psychiatrist Emil Kraepelin about a century ago 
(Kraepelin, 1919). The symptoms may vary considerably between patients and also 
within a single patent over time. The disease is mostly preceded by a prodromal phase, 
characterized by unspecific symptoms such as restlessness, anxiety, depressive and 
negative symptoms (see below), which can last several years before the patients 
experience their first psychotic episode (an der Heiden and Hafner, 2000). There is no 
specific diagnostic test and schizophrenia is diagnosed according to diagnostic manuals; 
Diagnostics and Statistical Manual of Mental Disorders (DSM-IV or the recently 
implemented new edition DSM-V; (American Psychiatric Association, 2000) or the 
International Classification of Diseases (ICD-10;WHO, 1992) and the symptoms are 
often divided into three broad clusters; positive symptoms, negative symptoms and 
cognitive deficits (Andreasen and Olsen, 1982, Gold and Harvey, 1993). Positive 
symptoms, sometimes referred to as psychotic symptoms, include delusions (such as 
thought broadcasting or communication with aliens), hallucinations (mostly auditory), 
formal thought disorder and catatonia. Negative symptoms include social withdrawal, 
flattened affect, apathy, anhedonia (inability to feel pleasure) and alogia (poverty of 
speech). Schizophrenia is associated with deficits in almost all cognitive domains, but 
with high a degree of interpersonal heterogeneity. The most characteristic cognitive 
impairments include deficits in working memory, attention and executive function, with 
less deficits found in other cognitive domains, e.g. spatial ability (Heinrichs and 
Zakzanis, 1998). Cognitive deficits in schizophrenia, indicated by e.g. low IQ and poor 
educational performance, pre-date the psychotic symptoms (Jones et al., 1994, David et 
al., 1997). Importantly, the severity of cognitive deficits, such as impaired verbal 
working memory and vigilance, predicts treatment outcome in schizophrenia to a higher 
degree than psychotic symptoms (Green, 1996), suggesting that treatments that 
effectively may ameliorate the cognitive impairments would be particularly 
advantageous. Cognitive impairments in schizophrenia are more stable than the 
psychotic symptoms, which may fluctuate considerably over time. Moreover, cognitive 
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deficits similar to those found in schizophrenia have been found in unaffected first-
degree relatives (Snitz et al., 2006), implicating cognitive deficits as an endophenotype 
of the disease. In addition to impairments in higher cognitive functions, deficiencies in 
sensory information processing (Braff et al., 1978) and motor speed and coordination 
(Flashman et al., 1996) have been found associated with schizophrenia, indicating a 
more general neuropsychiatric deficit that may reflect a neurodevelopmental 
impairment. 
1.7.2. Etiology of schizophrenia 
The cause or causes of schizophrenia are not known, however, both genetic and 
environmental factors have been found to contribute. For example, having a first-degree 
relative with schizophrenia significantly increases the risk of developing the disease 
(see e.g. Lichtenstein et al., 2009).  
Linkage and genome-wide association studies have found several susceptibility genes 
and short nucleotide polymorphisms that are associated with schizophrenia, some of 
which are shared with other disorders e.g. bipolar disorder. However, each gene variant 
seems to account for very little of the increased risk; rather it is the contribution of 
many gene variants that together convey an increased risk of developing schizophrenia 
(Harrison and Weinberger, 2005, Purcell et al., 2009, Ripke et al., 2013). Moreover, rare 
alleles conveying a high risk as well as de novo mutations may also play a role in the 
development of schizophrenia (for review see Doherty et al., 2012).  
In addition to susceptibility genes, several environmental factors have been found to 
increase the risk of acquiring schizophrenia. For example, several prenatal factors such 
as winter birth, obstetric complications, and intrauterine influenza infections have been 
proposed as risk factors for schizophrenia (for review see Bromet and Fennig, 1999). 
Furthermore, poor socioeconomic background (Bromet and Fennig, 1999), urban living 
(Lewis et al., 1992), migration (Cantor-Graae and Selten, 2005) as well as drug abuse, 
most notably use of certain stimulants and cannabis, has been found to increase the risk 
of developing schizophrenia (Andreasson et al., 1987, Callaghan et al., 2012).  
1.7.3. The dopamine hypothesis of schizophrenia 
The first indication that the dopamine system may be involved in schizophrenia was the 
discovery by Arvid Carlsson that chlorpromazine and haloperidol both enhanced the 
turnover of catecholamines (Carlsson and Lindqvist, 1963). They proposed that the 
effect represented a compensatory activation of the dopamine system due to a blockade 
of catecholamine receptors. Later it was found that a range of clinically used APDs 
were indeed dopamine receptor antagonists, subsequently identified as D2 receptor 
antagonists (Anden et al., 1966, Anden et al., 1970a, Creese et al., 1975, 1976, Seeman 
et al., 1976). It was observed that amphetamine, which enhances the release of 
catecholamines in the brain, may elicit or aggravate preexisting psychotic symptoms, 
which in turn could be blocked by APDs (Angrist et al., 1974). Moreover, L-DOPA, the 
precursor to dopamine, may also worsen psychotic symptoms in schizophrenic patients 
(Angrist et al., 1973). These findings lead to formulation of the dopamine hypothesis, 
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which suggests that schizophrenia is associated with an enhanced dopaminergic 
neurotransmission in the brain (Carlsson, 1978). Later studies demonstrated that 
although basal dopamine release is appears similar in patients and healthy subjects, 
amphetamine induces a larger dopamine release in the STR of schizophrenic patients 
than in healthy controls (Laruelle et al., 1996). This difference was only evident when 
the patients were in a psychotic state (Laruelle et al., 1999), indicating that the psychotic 
symptoms of schizophrenia may indeed be related to increased dopamine release. In 
addition to an enhanced subcortical dopaminergic transmission contributing to the 
positive symptoms of schizophrenia, several lines of evidence indicate that the negative 
symptoms may be related to impaired dopaminergic transmission in the PFC. This has 
led to a modified version of the dopamine hypothesis, which posits that an hyper-
reactive mesolimbic dopaminergic transmission is associated with the positive 
symptoms of schizophrenia, whereas a hypoactive mesocortical dopamine system may 
largely contribute to the negative symptoms and cognitive impairments.  
For example, schizophrenia is associated with hypofrontality i.e. reduced cerebral blood 
flow in the frontal lobes (Ingvar and Franzen, 1974) and some of the symptoms of 
schizophrenia resemble those observed in frontal lobe damage (Stuss and Benson, 
1984). Accordingly, schizophrenic patients taken as a group perform poorly in tasks that 
involve the PFC, e.g. working memory tests. This is associated with a hypoactivation of 
the dlPFC (Dreher et al., 2012). However, some schizophrenic patients with less 
working memory impairment may even display a hyperactivation of the dlPFC 
(Callicott et al., 2000).  
In contrast to the effect of D2 blockade on the positive symptoms, D2 receptor blockade 
has little effect on negative symptoms and cognitive impairments in schizophrenia and 
may, in fact, even worsen them (Carpenter, 1996, Saeedi et al., 2006). Interestingly, 
amphetamine, which exacerbates positive symptoms, may actually reduce negative 
symptoms and cognitive impairments in some patients (Laruelle et al., 1999, 
Lindenmayer et al., 2013). 
Results from studies in primates show that the PFC requires an optimal level of 
dopamine and D1 receptor activation for proper working memory function (Sawaguchi 
et al., 1988, Sawaguchi and Goldman-Rakic, 1991, Williams and Goldman-Rakic, 
1995). Dopamine D1 receptor activation display an inverted U-shape form, i.e. too little 
or too much dopamine in the PFC impairs working memory (Vijayraghavan et al., 
2007). Interestingly, amphetamine was found to enhance activation of the PFC in 
schizophrenic patients and to improve cognitive performance (Daniel et al., 1991), 
suggesting that low cortical dopamine level contribute to the cognitive deficits in 
schizophrenia. The ability of clozapine to preferentially potentiate dopamine release in 
the mPFC is suggested to underlie its effect on cognitive impairments and negative 
symptoms in schizophrenia (Moghaddam and Bunney, 1990, Nomikos et al., 1994, 
Goldman-Rakic et al., 2004). 
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Alterations in prefrontal dopamine transmission have also been found in patients. 
Several imaging studies have observed alterations in prefrontal D1 receptor binding in 
schizophrenic patients, further supporting a dysregulated dopaminergic transmission 
contributing to the symptoms. While Okubo and colleagues (Okubo et al., 1997) found 
the D1 receptor binding to be decreased in the PFC, correlating with negative and 
cognitive symptoms, Abi-Dargham and colleagues found the D1 receptor binding to be 
increased in the PFC (Abi-Dargham et al., 2002, Abi-Dargham et al., 2012). The higher 
D1 receptor binding correlated with poor working memory in one of the studies (Abi-
Dargham et al., 2002). The discrepancy between these seemingly contradictory studies 
may be attributed to methodological differences (for further discussion see Abi-
Dargham et al., 2002). Abi-Dargham and colleagues suggest that the enhanced number 
of D1 receptors may be due to a compensatory up-regulation of D1 receptors due to 
decreased dopamine stimulation. This conclusion was recently substantially supported 
by an imaging study, which demonstrated a reduced cortical dopamine release in 
schizophrenic patients (Abi-Dargham, 2011). 
1.7.4. Glutamate hypothesis of schizophrenia  
Dopamine is not the only neurotransmitter implicated in schizophrenia. In 1959, Luby 
and colleagues discovered that PCP, later shown to be a non-competitive NMDA 
receptor antagonist, could induce a schizophrenia-like state which was almost 
indistinguishable from schizophrenia (Luby et al., 1959, Javitt and Zukin, 1991). In 
similarity, ketamine, also a non-competitive NMDA receptor antagonist may induce 
positive and negative symptoms as well as cognitive impairments in healthy volunteers 
that are similar to those observed in schizophrenia (Krystal et al., 1994). Moreover, low, 
sub-dissociative doses of ketamine have been found specifically to impair verbal 
working memory in healthy volunteers, a common cognitive deficit in schizophrenia 
(Honey et al., 2003). Moreover, PCP, and other NMDA receptor antagonists have been 
found to worsen symptoms in schizophrenic patients (Luby et al., 1959, Lahti et al., 
1995, Malhotra et al., 1997).  
Several of the risk genes associated with schizophrenia have been shown to be linked to 
NMDA receptor-mediated signaling (e.g. DISC1 and dysbindin) and could contribute to 
an aberrant NMDA receptor-mediated transmission (Snyder and Gao, 2013). 
Genetically modified mice with reduced expression of the NMDA receptor subunit NR1 
display behavioral abnormalities analogous to schizophrenia for example deficits in 
social interaction (Mohn et al., 1999). 
Other data supporting the involvement of NMDA-receptor abnormalities in 
schizophrenia are derived from post mortem studies indicating alterations in the 
expression of several glutamatergic receptors in schizophrenia e.g. the NMDA receptor 
subunits NR2A and NR1 as well as associated postsynaptic proteins in the PFC 
(Dracheva et al., 2001, Kristiansen et al., 2007, Beneyto and Meador-Woodruff, 2008). 
More recently, alterations in the post-translational modifications of kainate and AMPA 
glutamatergic receptors have been identified. These modifications are thought to affect 
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translocation of the receptors (Tucholski et al., 2013a, Tucholski et al., 2013b), and may 
thereby also contribute to aberrant glutamatergic neurotransmission in schizophrenia.  
In addition to various alterations in the expression of glutamate receptors, patients 
suffering from schizophrenia have low cerebrospinal fluid (CSF) levels of the NMDA 
receptor co-agonist D-serine, an observation supported by findings from post mortem 
and genetic studies, suggesting that dysregulation of D-serine levels may contribute to 
NMDA receptor hypofunction (see Labrie et al., 2012). Thus, these observations 
propose that NMDA receptor hypofunction contributes to the symptoms of 
schizophrenia (Javitt and Zukin, 1991, Krystal et al., 1994). 
The involvement of both dopamine and glutamate in schizophrenia is not surprising 
since there is substantial interaction between the dopaminergic and glutamatergic 
systems in the brain and NMDA receptor antagonists have been shown to increase 
dopamine turnover in healthy volunteers (Krystal et al., 1994), affect dopamine cell 
firing rate and firing patterns (Murase et al., 1993b) and increase dopamine output in 
both cortical and subcortical areas of the brain see e.g. (Mathe et al., 1999). Dopamine 
D1 receptors and NMDA receptors interact on pyramidal cells in the PFC, a mechanism 
important for cognition (see 1.2.4). Moreover, ketamine-abuse has been reported to 
increase the number of D1 receptors in the dorsolateral PFC (dlPFC; Narendran et al., 
2005), in similarity to findings in schizophrenic patients (see above). 
In addition to dopamine and glutamate, also other neurotransmitters have been 
implicated in schizophrenia. For example, lysergic acid diethylamide (LSD) and other 
drugs acting as 5-HT2 agonists cause altered perception and hallucinations, implicating 
serotonin in schizophrenia (for review see e.g. Aghajanian and Marek, 2000). 5-HT2 
agonists suppress firing of serotonergic neurons in the raphe nuclei and may in addition 
increase glutamate release in the PFC. These effects have been shown to generate 
decreased synchronization of the activity of pyramidal cells in the PFC, which has been 
suggested to mediate hallucinations (Aghajanian and Marek, 2000). However, LSD and 
other 5-HT2 agonists mainly induce visual hallucinations, which are rarely observed in 
schizophrenia, and produce symptoms reminiscent of negative symptoms or cognitive 
impairments to a minor extent indicating that deficits in serotonergic transmission alone 
cannot explain the full symptomatology of schizophrenia. Moreover, increased levels of 
kynurenic acid, an endogenous substance derived from astrocytes, with antagonistic 
properties at the α7-nicotinic receptor and NMDA receptor has been found in the CSF of 
patients suffering from schizophrenia (Erhardt et al., 2001) although the 
pathophysiological significance of these findings remains to be fully understood. 
1.8. Antipsychotic drugs  
Before the introduction of APDs, the treatment of schizophrenic patients was limited to 
unspecific pharmacological treatments (such as opium or chloral hydrate) or to 
therapies, such as electroconvulsive therapy or even insulin shock. These treatments had 
in common that they had no sustained effect and as a result, patients often required 
frequent or life-long hospitalization. 
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1.8.1. Typical antipsychotic drugs (first generation antipsychotic drugs) 
The first drug to show a specific antipsychotic effect was chlorpromazine, a drug that 
was first synthesized in 1950. Chlorpromazine was originally developed as an 
antihistaminergic drug and was initially used to reduce shock after surgery. In 1952, 
chlorpromazine was found to alleviate symptoms of schizophrenia and mania (for 
review see (Lopez-Munoz et al., 2005), a finding that revolutionized psychiatric care 
and reduced the number of patients requiring hospitalization dramatically (c.f. 
Carpenter and Davis, 2012). At approximately the same time an extract from the plant 
Rauwolfia serpentina, which was used for the treatment of hypertension, containing 
among other substances reserpine and yohimbine, was also found to possess an 
antipsychotic action (see e.g. Kline, 1954). These findings spurred the search for other 
APDs and subsequently, in the same decade, Paul Janssen and colleagues developed 
haloperidol (Divry et al., 1958, Granger and Albu, 2005) a drug that was a much more 
selective dopamine receptor antagonist than chlorpromazine. These drugs (except 
reserpine), initially called major tranquilizers or neuroleptics, are now often referred to 
as typical APDs or first generation APDs and are still frequently used in the treatment 
of schizophrenia. 
The common mechanism of action of typical APDs is blockade of the D2 family of 
receptors, however affinity for other receptors may also contribute to the antipsychotic 
effect. To produce an antipsychotic effect, typical APD treatment must produce 
approximately 70% D2 receptor occupancy in STR (Farde et al., 1988a, Farde et al., 
1992). Unfortunately, a high degree of D2 blockade i.e. above 80% occupancy increases 
substantially the risk of EPS such as akathisia (inner restlessness and discomfort), 
dystonia (sustained involuntary muscle contractions), parkinsonism (tremor, 
hypokinesia and rigidity) and tardive dyskinesia (involuntary movement of e.g. the lips, 
tongue and extremities). Moreover, the typical APDs may increase prolactin levels, 
inducing endocrine side effects such as galactorrhea.  
Although typical APDs are generally effective in ameliorating positive symptoms of 
schizophrenia, they have less effect on negative and cognitive symptoms. In fact, 
treatment with D2 receptor antagonists, e.g. haloperidol, may even worsen negative 
symptoms, have a negative impact on mood and induce cognitive deficits in healthy 
volunteers (Carpenter, 1996, Saeedi et al., 2006). 
1.8.2. Atypical antipsychotic drugs (second generation antipsychotic drugs) 
In the 1950’s another APD that would also revolutionize the treatment of schizophrenia 
was first developed, namely clozapine. Based on its structure clozapine was initially 
thought to be an antidepressant drug, although subsequent studies in the mid 60’s by 
Hippius demonstrated its antipsychotic effects. However, in contrast to e.g. haloperidol, 
clozapine treatment was devoid of EPS in patients and did not induce catalepsy in 
laboratory animals; at that time thought prerequisite for antipsychotic activity. Because 
of this property, clozapine was considered an atypical APD compared to 
chlorpromazine and haloperidol (for review see Hippius, 1989, 1999). The discovery of 
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the atypical profile of clozapine has inspired the search for other atypical, or second 
generation APDs, with similar structure e.g. olanzapine and quetiapine.  
Clozapine has since then been found superior to both first generation and other second 
generation APDs in treatment-resistant schizophrenia (Kane et al., 1988, Taylor and 
Duncan-McConnell, 2000, McEvoy et al., 2006, Swartz et al., 2008). Furthermore, 
clozapine has been found to reduce suicidal behavior in schizophrenia and 
schizoaffective disorder (Meltzer et al., 2003, Hennen and Baldessarini, 2005). 
Clozapine exerts its antipsychotic effect at a low striatal D2 occupancy (~45%) 
compared to typical APDs which generally require almost 70% occupancy to exert an 
antipsychotic effect. As a consequence, clozapine has a very low risk of EPS (Farde et 
al., 1992, Nordstrom et al., 1995, Kessler et al., 2006b). Clozapine has higher affinity 
for several 5-HT receptors (including the 5-HT2 receptor) and the α2-adrenoceptor than 
for the D2 receptors (Schotte et al., 1996, Marcus et al., 2005). These properties have 
been proposed to contribute to the superior efficacy of clozapine in schizophrenia 
(Meltzer et al., 1989, Nutt, 1994, Hertel et al., 1999a, Svensson, 2003). Clozapine has 
also been shown to ameliorate negative symptoms and cognitive impairments in 
schizophrenia (Meltzer and McGurk, 1999, Leucht et al., 2009). Unfortunately, 
clozapine treatment may be associated with several severe side effects and, in fact, 
clozapine was even withdrawn from the market because of associated agranulocytosis 
(Idanpaan-Heikkila et al., 1977). The drug was subsequently reintroduced in 1990 
because of its superior efficacy (Kane et al., 1988), although patients receiving 
clozapine require regular hematological monitoring. In addition, clozapine treatment is 
often associated with weight gain and the metabolic syndrome (Mitchell et al., 2013). 
Despite these severe side effects and the fact that clozapine is mostly prescribed to 
treatment-resistant patients, the use of clozapine is associated with the lowest mortality 
rates compared with all other APDs investigated (Tiihonen et al., 2009).  
The effect of clozapine on negative symptoms and cognitive impairments is thought to 
be related to the increased dopamine output in the PFC (Imperato and Angelucci, 1989, 
Moghaddam and Bunney, 1990, Nomikos et al., 1994). Subsequently, also other 
atypical APDs have been found to increase dopamine output in the PFC (see e.g. (Li et 
al., 1998). The mechanism by which atypical APDs induce the cortical dopamine 
release is not entirely clear, although it may involve a blockade of 5-HT2A and D2 
receptors and indirect activation of 5-HT1A (Ichikawa et al., 2001, Ichikawa et al., 2002, 
Liegeois et al., 2002). In addition to the blockade of 5-HT2A receptors, clozapine 
induces dopamine release in the PFC by blockade of α2-adrenoceptors (see Hertel et al., 
1999a, Devoto et al., 2003). Affinity for other receptors may also contribute to the 
antipsychotic effect, for example, clozapine acts as partial agonist at D1 and 5-HT1A 
receptor (Salmi et al., 1994a, Newman-Tancredi et al., 1996).  
In addition to the increased cortical dopamine release, clozapine, as well as other 
atypical APDs, has been found to facilitate both NMDA-induced currents and EPSPs in 
pyramidal cells in cortical slices, an effect which may also contribute to the superior 
effect of clozapine on negative symptoms and cognitive deficits in schizophrenia 
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(Arvanov et al., 1997, Ninan et al., 2003b). The facilitation of NMDA-induced currents 
and EPSPs induced by APDs, at is least in part, dependent on activation of the 
dopamine D1 receptors (Chen and Yang, 2002, Ninan and Wang, 2003, Jardemark et al., 
2010). The effect of clozapine has been found to be mediated by PKA and protein 
kinase C (PKC) as well as the calcium/calmoduline-dependent kinase II (CaMKII) 
(Jardemark et al., 2003, Ninan et al., 2003a, Wittmann et al., 2005). Interestingly, 
clozapine reduced the binding of a selective tracer that binds to the PCP site of the 
NMDA receptor, indicating that clozapine indeed activates NMDA receptor-mediated 
transmission in patients (Bressan et al., 2005). In contrast to the effects on NMDA 
receptor-mediated transmission, atypical APDs such as olanzapine or clozapine have 
not been found to affect AMPA receptor-mediated transmission in the mPFC (Arvanov 
et al., 1997, Ninan et al., 2003b). 
Preclinical studies have shown that, in addition to its importance in cognition, dopamine 
transmission in the mPFC, especially D1 receptor activation, modulates dopamine 
release in the NAc and subcortically derived D2 receptor mediated behaviors (Pycock et 
al., 1980, Vezina et al., 1991, Scornaiencki et al., 2009). Thus, dopamine in the cortex 
acting on D1 receptors may contribute to regulate dopamine-mediated behaviors 
controlled by subcortical dopamine pathways.  
Low doses of L-DOPA given with APDs may augment the effect of APDs in 
schizophrenia (Jaskiw and Popli, 2004). L-DOPA treatment increases dopamine levels 
more in the PFC that in the NAc (Loeffler et al., 1998) and when combined with a low 
sub-effective dose of raclopride, L-DOPA treatment potentiates the suppression of CAR 
behavior and, in parallel, induces a preferential increase in dopamine output in the 
mPFC (Eltayb et al., 2005) supporting the notion that enhanced cortical dopamine levels 
per se contributes to an antipsychotic effect. 
A number of atypical APDs have been developed since the discovery of clozapine. 
There is considerable diversity among them with regard to their receptor binding 
profiles as well as clinical efficacy. As a group, atypical APDs have a broader receptor 
binding profile than typical APDs, with affinity for a wide range of receptors which 
contributes to their antipsychotic effect. Most atypical APDs have high affinity for 
several serotonergic receptors, most notably 5-HT2A/C receptors.  
For example, olanzapine is an atypical APD that is structurally similar to clozapine and 
has, in similarity to clozapine, higher affinity for e.g. 5-HT2A, 5-HT2C, 5-HT6 and the 
histamine H1 receptor than for the D2 receptor (Schotte et al., 1996). However, in 
contrast to clozapine, olanzapine lacks high affinity for the α2-adrenoceptor (Shahid et 
al., 2009). Olanzapine has been found effective against positive and negative symptoms 
in schizophrenia but unfortunately, olanzapine treatment is often associated with side 
effects such as the metabolic syndrome and weight gain (Beasley et al., 1997). Positron 
emission tomography (PET) studies in patients, show that olanzapine treatment produce 
a very high occupancy on the 5-HT2 receptors (>90% even at 5 mg/day) and a D2 
occupancy which was generally higher (i.e. 55 - 88%) than that obtained with clozapine 
Carl Björkholm 
22 
 
(Nordstrom et al., 1995, Kapur et al., 1998) and, in fact, similar to that observed in 
patients receiving typical APDs (Zipursky et al., 2005).  
Interestingly, the atypical APD quetiapine is effective at lower D2 receptor occupancy 
than olanzapine and similar to that obtained with clozapine treatment (Borison et al., 
1996, Arvanitis and Miller, 1997, Kessler et al., 2006b). Consequently, quetiapine 
treatment is associated with very low risk of EPS or increased prolactin levels (Borison 
et al., 1996, Arvanitis and Miller, 1997). In addition to its effect in schizophrenia, 
quetiapine is effective as monotherapy in bipolar disorder and MDD in approximately 
the same dose range (Calabrese et al., 2005, Cutler et al., 2009). Quetiapine has been 
found to possess higher affinity for 5-HT2A, 5-HT1A, α-adrenoceptors and H1 receptors 
than the D2 receptors (Schotte et al., 1996). In a clinical study investigating the effects 
of atypical APDs in schizophrenia, quetiapine was found to be more efficacious 
compared to other atypical APDs in relieving certain neurocognitive deficits in 
schizophrenia (Riedel et al., 2010). However, it should be noted that clozapine was not 
included in the study.  
One of the newest atypical APDs is asenapine. Asenapine has a multi-receptor binding 
profile and has higher affinity for several receptors (5-HT2A, 5-HT2b, 5-HT2c, 5-HT6 and 
5-HT7, α2B and D3) than for the D2 receptor (Shahid et al., 2009). In clinical studies, 
asenapine was found efficatious in reducing positve as well as negative symtoms of 
schizophrenia, with little metabolic disturbances or weight gain (Potkin et al., 2007, 
Schoemaker et al., 2010). In additon, asenapine has been found effective in mania as 
well as to reduce depressive symtoms in mixed states associated with bipolar disorder 
(Vita et al., 2013). Preclincal studies propose that asenapine may be effective in 
ameliorating cognitive deficts associated with schizophrenia and that this effect may be 
mediated via D1 receptor activation in the mPFC (Jardemark et al., 2010, Snigdha et al., 
2011, Elsworth et al., 2012).  
The drug raclopride was originally developed as an APD and is a highly selective D2/3 
receptor antagonist. Raclopride was found to produce an antipsychotic in clinical 
studies (Farde et al., 1988b). However, raclopride is not used clinically but is widely 
used as pharmacological tool in e.g. PET studies (then as 11C-raclopride) (Farde et al., 
1985, Kohler et al., 1985).  
All the above mentioned APDs have shown antipsychotic-like effect in preclinical 
models (Hillegaart and Ahlenius, 1987, Moore et al., 1992, Wadenberg et al., 2001, 
Franberg et al., 2008). Using microdialysis, the atypical APDs olanzapine, quetiapine 
and asenapine have all been shown to increase dopamine and noradrenaline output in 
the rat PFC and to a lesser extent dopamine output in the NAc (Li et al., 1998, Ichikawa 
et al., 2002, Franberg et al., 2008, Franberg et al., 2009, Yamamura et al., 2009). 
Raclopride, having a typical APD profile, preferentially enhances dopamine output in 
the NAc, compared to the mPFC (Hertel et al., 1999a), an effect similar to that of 
haloperidol. Interestingly, asenapine has also been found to increase serotonin output in 
the mPFC, an effect not obtained by olanzapine and quetiapine (Li et al., 1998, 
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Ichikawa et al., 2002, Franberg et al., 2009, Yamamura et al., 2009). In similarity with 
clozapine, the atypical APDs olanzapine, quetiapine and asenapine all have been found 
to facilitate NMDA receptor-mediated currents in pyramidal cells, using intracellular 
recordings in vitro (Ninan et al., 2003b, Franberg et al., 2008, Jardemark et al., 2010). 
Raclopride however, does not affect NMDA-induced currents in pyramidal cells, in line 
with its typical profile (Jardemark et al., 2009). 
The atypical APD aripiprazole acts as a partial agonist at the D2 receptor, and is 
sometimes called a third generation APD. Partial agonism at the D2 receptor is thought 
to stabilize rather than to block dopaminergic transmission (Keck and McElroy, 2003). 
In addition to D2 partial agonism, aripiprazole is a partial 5-HT1A agonist and a 5-HT2A 
antagonist. Aripiprazole treatment is associated with low risk for EPS and prolactin 
increase as well as weight gain (Keck and McElroy, 2003).  
1.8.3. Adjunctive antidepressants added to APDs in schizophrenia 
In a series of studies, Tiihonen and colleagues have shown that addition of the 
antidepressant drug mirtazapine to typical APDs may improve positive and negative 
symptoms, as well as cognitive deficits and depressive symptoms in schizophrenia 
(Joffe et al., 2009, Stenberg et al., 2010, Terevnikov et al., 2010, Stenberg et al., 2011, 
Terevnikov et al., 2011). Mirtazapine is an α2A/C-adrenoceptor and at 5-HT2C receptor 
antagonist, which preferentially increases dopamine and noradrenaline output in the 
frontal cortex with little effect in the NAc (Millan et al., 2000). Thus, addition of 
mirtazapine to low doses of APD generates a binding profile reminiscent of clozapine 
(c.f. 1.8.2). Similarly, addition of selective α2-adrenoceptor antagonists (e.g. idazoxan) 
to typical APD may reduce both positive and negative symptoms of schizophrenia 
(Litman et al., 1996, Hecht and Landy, 2012).  
1.9. Bipolar disorder 
Bipolar disorder, sometimes called manic-depressive disorder, is a disease characterized 
by shorter manic (bipolar depressive disorder type I) or hypo-manic episodes (bipolar 
disorder type II) followed by longer euthymic and/or depressive episodes (Judd et al., 
2002). Cyclothymic disorder and bipolar disorder not otherwise specified are also 
considered to belong to the bipolar disorder spectrum. Depression is more prevalent 
than mania and it is estimated that bipolar patients experience depressive symptoms 
approximately 1/3 of the time (Judd et al., 2002). Moreover, patients with bipolar 
disorder also experience subsyndromal depressive symptoms which are associated with 
impairment at work and in social life (Altshuler et al., 2006). The lifetime prevalence of 
bipolar disorder is estimated to approximately 1% (Regier et al., 1988), but is 
considered by some to be substantially higher (Akiskal et al., 2000) mainly due to the 
fact that many patients with an MDD diagnosis experience shorter episodes of mania or 
hypomania without receiving a bipolar diagnosis. A recent longitudinal study found that 
approximately one third of the patients that had an MDD diagnosis later receive a 
bipolar diagnosis, a finding that may explain treatment-resistance in some MDD 
patients (Dudek et al., 2013).  
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The manic episodes are characterized by periods of elevated mood, irritability, reduced 
need for sleep and may include delusive symptoms such as grandiose delusions and 
florid religious beliefs. Some patients may also exhibit psychotic symptoms resembling 
those seen in schizophrenia. Manic episodes may be experienced as positive by the 
patient, however, their irresponsible behavior most often causes conflicts with family 
and colleagues and, consequently, bipolar patients in a manic state may require 
hospitalization, often against their will. The risk of suicide amongst bipolar patients is 
very high, approximately 20 times higher than in the general population (Tondo et al., 
2003).  
Cognitive functions such as executive function, working memory and attention is 
impaired in bipolar disorder (Goldberg and Chengappa, 2009) although to a lesser 
extent than in schizophrenia (Daban et al., 2006). Interestingly, cognitive function is 
impaired not only in manic or depressed states but also in the euthymic state (Martinez-
Aran et al., 2004) and is apparent also in first degree relatives (Ferrier et al., 2004), 
indicating that impaired cognition is a trait for bipolar disorder. Moreover, in bipolar 
disorder, impaired cognition is associated with poor occupational functioning 
(Martinez-Aran et al., 2004). 
1.9.1. Etiology of bipolar disorder 
The etiology of bipolar disorder is not fully understood. In similarity with 
schizophrenia, there is a substantial genetic contribution also to bipolar disorder, some 
of which is shared with schizophrenia (Lichtenstein et al., 2009, Craddock and Sklar, 
2013).  
Environmental factors such as obstetric complications or winter-spring birth and 
parental loss are suggested to contribute to the risk of developing bipolar disorder, 
however there are discrepancies between studies (for review see Tsuchiya et al., 2003). 
Moreover, stressful life events, altered circadian rhythm, childbirth and use of 
antidepressants may precipitate a manic episode in bipolar patients (Proudfoot et al., 
2011).  
Imaging studies of anatomical or functional brain alterations in bipolar disorder have 
largely yielded inconsistent results (see e.g. Nery et al., 2013), however, in similarity to 
schizophrenia, bipolar disorder has been associated with an altered expression of 
glutamate receptors in several brain areas including the PFC (Beneyto et al., 2007, 
Beneyto and Meador-Woodruff, 2008). 
1.9.2. Treatment of bipolar disorder 
Several different types of drugs are used in the treatment of bipolar disorder, partly 
depending on in which state of the disease the patient is. Lithium is effective as a mood-
stabilizing drug in preventing conversion to mania or depression (Cade, 1949, Geddes et 
al., 2004). Lithium is also effective in reducing suicide in mood disorders (Cipriani et 
al., 2005). The mechanism of action of lithium is complex and not fully understood and 
may include effects on both neurotransmitter release and intracellular processes (Malhi 
et al., 2013). Although generally effective, lithium has a narrow therapeutic interval and 
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may induce hypothyroidism and affect renal function (McKnight et al., 2012). In 
addition antiepileptic drugs are used as mood stabilizers, however, the efficacy differs 
between drugs (Cipriani et al., 2011, Geddes and Miklowitz, 2013). Although lithium 
and the antiepileptic drugs may alleviate an acute manic episode, recent data suggests 
that APDs such as haloperidol or risperidone have a better effect on manic symptoms 
than the mood stabilizers (Cipriani et al., 2011). 
Monotherapy with antidepressant drugs such as SSRIs seems to have limited effects on 
bipolar depression (Sidor and MacQueen, 2012). Atypical APDs are often combined 
with antidepressants generating a mood stabilizing effect, and thus prevent conversion 
to mania or depression. Interestingly, such combinations have also been found to 
produce an enhanced antidepressant effect in MDD and bipolar depression, with a rapid 
onset (see 1.11.1).  
The atypical APD quetiapine has gained widespread use in bipolar disorder and has 
been found effective in ameliorating both manic (Cipriani et al., 2011) and depressive 
(McElroy et al., 2010, Young et al., 2010) episodes as well as to increase the time to 
relapse of depressive events (Young et al., 2012). In a recent study investigating the 
efficacy of different drugs used to treat mania and depression, quetiapine was found to 
be almost equally effective in treating mania and depression (Popovic et al., 2012). 
1.10. Major Depressive Disorder  
Depression is an affective disorder characterized by periods of low mood interchanged 
with periods of euthymia. Depression is very common and twice as common in women 
as in men, with an estimated 12 month prevalence of approximately 7 % (Kessler et al., 
2003, Wittchen et al., 2011) and lifetime prevalence is estimated to approximately 15 to 
20 % (Kessler et al., 2003, Kessler et al., 2005). Co-morbid disorders, such as anxiety, 
substance use and impulse control disorder are very common and correlates with the 
severity of depressive symptoms (Kessler et al., 2003). Recent figures shows that 
depression affects 30 million people yearly in the European Union alone, and of all 
mental and neurological disorders depression is associated with the highest burden of 
disease (measured as disability-adjusted life years, DALYs) in Europe (Wittchen et al., 
2011). Due to the high prevalence and the severity of symptoms, mood disorders, i.e. 
MDD and bipolar disorder, leads to the highest costs for society of all disorders of the 
brain (Gustavsson et al., 2011), costs which are mainly accounted for by indirect costs, 
e.g. absence from work and low productivity (Kessler et al., 2003, Kessler et al., 2006a, 
Gustavsson et al., 2011). Another severe consequence of depression is an increased risk 
of suicide. Co-morbid disorders and other risk factors (e.g. severity of the depression, 
anxiety disorder and drug use) significantly increase the risk of suicide in depression 
(Hawton et al., 2013).  
Like schizophrenia and bipolar disorder, depression is diagnosed by a clinical 
evaluation according to DSM-IV or ICD-10. The symptoms of depression are diverse 
and to be diagnosed with a depressive episode according to DSM-IV, one of the two 
cardinal symptoms must be fulfilled; either depressed mood most of the day or 
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diminished interest or pleasure in all or most activities for at least two weeks. In 
addition, five of the following symptoms are required; unintentional weight gain or loss, 
hypersomnia or insomnia (early morning awakenings are very common), psychomotor 
agitation or retardation noticed by others, feelings of worthlessness or excessive guilt, 
fatigue or loss of energy, diminished ability to think or concentrate or indeciveness, 
recurrent thoughts of death or suicide. Given the diversity of symptoms, it is possible 
for two depressed patients not to share a single symptom further illustrating the 
heterogeneity of MDD. 
1.10.1. Etiology of major depressive disorder 
The etiology of depression remains to be fully understood. The heritability of MDD has 
been estimated to 40% (Kendler et al., 2006), which is lower than for schizophrenia and 
bipolar disorder. Risk genes have been found but the results have been difficult to 
replicate and seem to convey little of the increased risk of MDD (Shyn and Hamilton, 
2010). One explanation for difficulties in finding candidate genes is that there seems to 
be a considerable gene x environment interaction for the risk of developing MDD (see 
e.g. Caspi et al., 2003).  
MDD is associated with cognitive impairment, in domains such as working memory, 
emotional processing and attention, and these deficits may persist even after remission 
(Taylor Tavares et al., 2003, Preiss et al., 2009, Bora et al., 2012). Antidepressant drugs 
usually do not affect dopaminergic transmission which may have bearing on the relative 
lack of efficacy of these drugs, since there are several indications for an impaired 
dopamine system in MDD, especially for symptoms such as cognitive deficits, reduced 
drive and anhedonia (Nestler and Carlezon, 2006, Dunlop and Nemeroff, 2007).  
1.10.2. Hypotheses of depression 
The first drugs found to have antidepressant effect were iproniazid and imipramine, 
which were discovered by serendipity in the 1950’s. At the time, the mechanism 
conveying the antidepressant effect was unknown but both drugs were found to increase 
the availability of monoamines in brain; iproniazid by inhibiting the enzyme 
monoamine oxidase (MAO) and imipramine by inhibiting the reuptake of monoamines. 
Based on the mechanism of action of these drugs and the fact that reserpine, a drug 
which reduces monoamine levels may induce depressive symptoms, it was hypothesized 
that depression was caused by a deficiency in monoamines, in particular noradrenaline, 
in the brain (see e.g. Schildkraut, 1965). Since then, many antidepressant drugs with 
different mechanism of action have been developed that all have in common that they 
enhance monoaminergic transmission in the brain. However, although augmented 
monoaminergic transmission may ameliorate depressive symptoms, it has been difficult 
to actually demonstrate reduced levels of monoamines in depressed patients, indicating 
that it may not be a monoamine deficiency per se that causes depression. Although, 
antidepressant drugs increase monoamine levels within hours after administration, the 
antidepressant response is usually delayed and patients may require treatment for weeks 
to months to be fully effective (Trivedi et al., 2006). One explanation to the delayed 
effect may be that the initial increase in monoamine levels is attenuated by inhibitory 
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autoreceptors (e.g. α2 and 5-HT1A) which desensitize over time allowing for the full 
antidepressant response (Svensson and Usdin, 1978, see  Nutt, 2002). Moreover, studies 
in animals have shown that repeated dosage of antidepressants increases cortical 
plasticity (Maya Vetencourt et al., 2008) and may induce neurogenesis in the 
hippocampus of rodents (Malberg et al., 2000), effects which if existing in humans 
might contribute to explain the delayed antidepressant effect. In contrast, in a series of 
experiments Harmer and colleagues have shown that antidepressant drugs reduce a 
negative bias in emotional processing associated with MDD (Harmer, 2008). This effect 
is already observable within a few hours of drug administration and thus precedes the 
effects on mood and the authors suggest that antidepressant drugs do not enhance mood 
per se but rather affect the emotional processing which subsequently also reduces 
depressive symptoms. 
Stress is a major risk factor for developing depression and chronic stress has been found 
to affect the morphology of pyramidal cells in the rat cortex. Repeated stress may 
induce atrophy of the dendrite arbor of layer V pyramidal cells of the rat mPFC (Liu 
and Aghajanian, 2008). The stress-induced atrophy has biological consequences as it 
reduces the excitatory input to the pyramidal cells. Indeed, MDD has been found to be 
associated with a dysregulated hypothalamic-pituitary-adrenal (HPA) axis, and stressful 
life-events is associated with the onset of depression (Kendler et al., 1995, Krishnan and 
Nestler, 2010). The dysregulated HPA axis is suggested to contribute to the observed 
neuronal atrophy as well as the symptomatology of MDD. However, hypercortisolemia 
is mostly found in severely depressed patients requiring hospital care and a subset of 
depressed patients actually display hypocortisolemi (Krishnan and Nestler, 2010). 
Depression is associated with dysfunction in brain networks that regulate mood and 
emotion, and both imaging and post-mortem studies show a reduced gray matter volume 
and altered activity in several areas of the brain, including sub-divisions of the PFC, 
cingulate cortex, hippocampus and the ventral striatum, although some conflicting 
results have been obtained (Drevets et al., 2008). In the PFC, post-mortem studies have 
demonstrated a reduced size of neurons and number of glia cells, alterations that seem 
to be specific for depression (Rajkowska et al., 1999). A recent study found a reduced 
number of synapses and expression of several genes associated with synapse function in 
the dlPFC of patients suffering from MDD (Kang et al., 2012). Moreover, a reduced 
prefrontal expression of NR1, NR2A, NR2B, mGluR5 and PSD-95 (Beneyto and 
Meador-Woodruff, 2008, Feyissa et al., 2009, Deschwanden et al., 2011) as well as 
increased expression of mGluR2/3 receptors (Feyissa et al., 2010) has also been 
observed in depressed patients.  
1.11. Antidepressant drugs 
Imipramine was the first in what became a whole class of drugs called tricyclic 
antidepressants, which received the name because of their structure. The tricyclic drugs 
are effective in depression (Kuhn, 1958), however they have affinity for e.g. 
histaminergic and cholinergic receptors, and may cause serious side effects, including 
QT prolongation and cardiac death. Such side effects made the tricyclics far from 
Carl Björkholm 
28 
 
optimal in the treatment of depression, and therefore more selective reuptake inhibitors 
were developed. 
Since the introduction of the first SSRI, zimelidine around 1980, several other SSRIs 
have been developed and have now become available (e.g. sertraline, fluoxetine and 
citalopram). SSRIs increase synaptic levels of serotonin by inhibiting the SERT. 
Numerous clinical studies have shown a significant antidepressant effect of the SSRIs 
(see e.g. Trivedi et al., 2006) and the increased use of SSRIs has been found to correlate 
well with the reduction in suicide rates observed during the last 20 years (Gibbons et al., 
2005). SSRIs are associated with fewer and much less serious side effects than the 
tricyclic drugs and are now widely used and are the first line treatment for depression. 
However, the efficacy of SSRIs is less than optimal. In similarity with TCAs, SSRIs 
have a delayed onset of the antidepressant effect (Trivedi et al., 2006) and, importantly 
only about one third achieve full remission. In fact, significant symptom relief is only 
achieved in approximately 50% of patients treated with SSRIs (Trivedi et al., 2006).  
The first SSRI that gained worldwide use is fluoxetine (Wong et al., 2005). In clinical 
trials, fluoxetine was found as effective as imipramine but with less side effect (Stark 
and Hardison, 1985). In addition to MDD, fluoxetine and other SSRIs has been found 
effective in other psychiatric disorders e.g. obsessive compulsive disorder and anxiety 
disorders (Wong et al., 2005). Preclinical studies have shown fluoxetine to increase 
extracellular serotonin levels in several brain regions and to be effective in animal 
models of depression (see Wong et al., 1995 and references therein). In a study using 
intracellular recordings, fluoxetine was found to increase NMDA-induced currents in 
pyramidal cells of the rat mPFC at 1 µM, but not at 200 nM (Arvanov et al., 1997). 
Another commonly used SSRI is escitalopram which is the the S-enatiomer of 
citalopram (which is a a racemate containing both R- and S-enantiomers) with high 
selectivity for the SERT. Experimetnal data indicates that the R-enantiomer of 
citalopram antagonizes some of the effects S-enantiomer (see e.g. Sanchez, 2006, 
Schilström et al., 2011). Escitalopram shows a potent effect in animal models predictive 
of antidepressant activity and increases serotonin output in the mPFC (Sanchez et al., 
2003, Pehrson et al., 2013). Moreover, escitalopram facilitates NMDA receptor-
mediated transmission in pyramidal cells of the rat mPFC in vitro and appaers to 
possess a cognitive enhancing action in experimental animals (Schilstrom et al., 2011). 
Escitalopram is seems to generate an enhanced antidepressant activity compared with 
other SSRIs, (including citalopram) with a faster onset of action (Montgomery et al., 
2007, Montgomery and Moller, 2009). Escitalopram has also been found to alleviate 
certain cognitive imparments in depressed patients (Wroolie et al., 2006, Herrera-
Guzman et al., 2009).  
In addition to SSRIs, a selective noradrenaline reuptake inhibitor (NRI), reboxetine has 
been developed for depression. Early clinical studies indicated that reboxetine may be 
as effective as SSRIs in depression and was found to increase drive, cognition and 
social functioning in depressed patients, although with different side effect profile when 
compared with SSRIs (Montgomery, 1997, Schatzberg, 2000, Ferguson et al., 2003). In 
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preclinical studies, reboxetine has been found to possess an antidepressant-like effect, 
improve measures of cognitive function, increase dopamine and noradrenaline output in 
mPFC and the hippocampus as well as to increase burst firing of dopaminergic cell 
bodies within the VTA (Sacchetti et al., 1999, Wong et al., 2000, Linner et al., 2001, 
Borgkvist et al., 2011, De Bundel et al., 2013). Significantly, atomoxetine, an NRI used 
in attention deficit hyperactive disorder (ADHD) has been found to enhance cognition 
also in healthy volunteers (Chamberlain et al., 2006).  
Several other antidepressant drugs acting on the reuptake of monoamines have been 
developed, such as bupropion, a dopamine and noradrenaline reuptake inhibitor (Thase 
et al., 2005). Venlafaxine and duloxetine are serotonin and noradrenaline reuptake 
inhibitors (Golden and Nicholas, 2000, Mallinckrodt et al., 2007). In addition to 
reuptake inhibitors, there are several other drugs that enhance monoaminergic 
transmission which can be used in depression, e.g. the reversible MAO-A inhibitor 
moclobemide (Shulman et al., 2013) and mirtazapine, which is an α2 and 5-HT2C 
receptor antagonist (Millan et al., 2000).  
1.11.1. Rapidly acting antidepressant drugs  
In 1990, Trullas and Skolnick reported that NMDA receptor antagonists possess 
antidepressant-like activity in preclinical studies (Trullas and Skolnick, 1990). An 
antidepressant effect of the non-competitive NMDA receptor antagonist ketamine was 
subsequently demonstrated in patients by Berman and colleagues (Berman et al., 2000). 
Moreover, the antidepressant effect had a very rapid onset (within hours) and was found 
to be sustained over several days after a single administration, despite the short half-life 
of ketamine (Clements et al., 1982). This original study has since been replicated and 
extended several times. For example, Zarate and colleagues showed that the 
antidepressant effect of ketamine at a single dose may last up to 2 weeks and that 
ketamine is effective also in bipolar depression and may reduce suicidal ideation (Zarate 
et al., 2006, Zarate et al., 2012). However, the use of ketamine is limited by side effects 
such as abuse liability and, as previously mentioned, since ketamine may induce 
psychotic symptoms (Krystal et al., 1994). 
The robust antidepressant-like effect of ketamine observed also in preclinical models 
has been shown to be dependent on activation on AMPA receptors in the mPFC as well 
as activation of the mammalian target of rapamycin (mTOR) signaling pathway (Maeng 
et al., 2008, Li et al., 2010). Ketamine was found to induce an increased in synaptic 
proteins, e.g. GluR1, growth of dendritic spines and enhanced glutamatergic 
transmission in the mPFC, including increased release of glutamate in the mPFC of 
awake rats following acute administration of ketamine (Moghaddam et al., 1997). 
Interestingly, clinical studies show that a single intravenous dose of the muscarinic 
acetylcholine receptor antagonist scopolamine can generate a rapid and sustained 
antidepressant effect (Furey and Drevets, 2006, Drevets and Furey, 2010). Moreover, 
the mode of action of scopolamine seems to involve AMPA receptor activation as well 
as the mTOR pathway, in analogy with ketamine (Voleti et al., 2013).  
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Needless to say, the underlying mechanisms of the action of ketamine in primates 
appear to be complex. Thus, for example, a recent study in monkeys reported that low 
doses of ketamine increased serotonergic transmission by inhibiting the activity of the 
SERT, which may contribute to the antidepressant effect of ketamine (Yamamoto et al., 
2013). 
 1.11.2. Adjunctive atypical APDs in bipolar disorder and MDD 
In general, most APDs are effective in ameliorating manic symptoms in bipolar disorder 
(Cipriani et al., 2011). Importantly, several studies show that adjunct treatment with 
atypical APDs can be used to augment the effect of antidepressants in bipolar 
depression as well as treatment-resistant MDD (Nelson and Papakostas, 2009, Cruz et 
al., 2010). In addition, to an enhanced antidepressant effect, in analogy with that of 
ketamine, combined treatment with atypical APDs and antidepressant drugs may also 
generate a fast onset of the antidepressant effect, which may be observed as early as 
within 4-5 days (Calabrese et al., 2005, Dube et al., 2007, Cruz et al., 2010, Tohen et 
al., 2010) as opposed to several weeks with an SSRI alone (Trivedi et al., 2006). 
Thus, the atypical APD olanzapine has been found to augment the antidepressant effect 
of fluoxetine in treatment-resistant MDD and bipolar depression (Brown et al., 2009, 
Tohen et al., 2010) and a fixed combination of olanzapine and fluoxetine is marketed in 
the US for this purpose.  
The atypical APD quetiapine has been shown to reduce depressive symptoms in MDD 
both as adjunct treatment as well as when used as monotherapy (Cutler et al., 2009, 
Bauer et al., 2010). Quetiapine exerts an antidepressant effect also in bipolar depression 
(Calabrese et al., 2005, McElroy et al., 2010, Young et al., 2010). The APD, quetiapine 
seems to induce a genuine antidepressant effect since quetiapine monotherapy reduced 9 
out of 10 of the MADRS subscales, including core symptoms (Calabrese et al., 2005). 
One explanation may be that quetiapine produces an active metabolite in humans, 
norquetiapine, which differs from quetiapine in its high affinity for the NET, which has 
been suggested to mediate the antidepressant effect of quetiapine (Jensen et al., 2008). 
In contrast to the human situation, norquetiapine is however not formed in rodents to 
any significant extent (Hudzik et al., 2008). Quetiapine treatment has been found to 
induce an approximate 3:1 quetiapine: norquetiapine plasma ratio in patients (Nikisch et 
al., 2010) and recent PET studies data have shown that quetiapine treatment results in 
significant NET occupancy (Nyberg et al., 2013). 
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2. Specific aims of this study 
 
 To examine whether reboxetine may provide a means, by NET inhibition, to 
enhance the efficacy of low doses of olanzapine, and potentially contribute to 
mimic some of the preclinical profile of clozapine. 
 
 To investigate whether NET inhibition, which is generated in patients by 
norquetiapine, may contribute to the antipsychotic effect of quetiapine. 
 
 To evaluate adjunctive administration of the novel atypical APD asenapine to 
the SSRI escitalopram on cortical monoamine output, accumbal dopamine 
output, cortical NMDA- and AMPA receptor-mediated transmission, 
respectively, as well as the effects on electrically evoked EPSPs in the mPFC. 
 
 To analyze the neurobiological effects of adjunct administration of olanzapine 
when added to fluoxetine, as well as to compare these effects with the 
corresponding effects of a single dose of ketamine with regard to cortical 
NMDA and AMPA receptor-mediated transmission in the mPFC. 
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3. Materials and methods 
3.1. Animals 
Male albino rats of the Wistar strain were used for behavioral and in vivo microdialysis 
experiments and male albino Sprague Dawley rats were used for the in vitro 
electrophysiological recordings. Rats were obtained from B&K Universal, (Sollentuna, 
Sweden; Manuscript I and II) and Charles River (Germany; Manuscript II, III and IV). 
Food and water was available ad libitum and the rats were housed under standard 
laboratory conditions with controlled temperature and humidity. For behavioral 
experiments, rats were kept on a reversed day/night (12 h/12 h) cycle with lights off at 6 
am whereas for the other experiments animals where kept on a 12 h/12 h day/night 
cycle with lights on at 6 am. Experiments were approved by, and conducted in 
accordance with, the local animal ethics committee, Stockholm North and the 
Karolinska Institutet. 
3.2. Drugs 
Olanzapine was a gift from Eli Lilly (USA), quetiapine fumarate as well as raclopride 
tartrate were gifts from AstraZeneca (Sweden), asenapine was a gift from Schering-
Plough (UK) and Merck Sharp & Dohme Corp (MSD; UK), and escitalopram was a gift 
from Lundbeck A/S (Denmark). Fluoxetine was obtained from Ascent Scientific 
(Bristol, UK). Tetrodotoxin (TTX), bicuculline and 2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl) propionic acid (AMPA) were obtained from Tocris (Bristol, UK). 
Glycine, ketamine and N-methyl-D-aspartic acid (NMDA) was obtained from Sigma 
(St. Louis, MO, USA). SCH23390 HCl was obtained from RBI.  
3.3. Conditioned avoidance response test 
The conditioned avoidance response (CAR) test is a behavioral model used to assess 
antipsychotic-like activity of drugs, based on Ivan Pavlov’s work on conditioned stimuli 
(CS) and unconditioned stimuli (UCS; Courvoisier, 1956). The CAR test has been used 
since the 1950’s and has high predictive validity for antipsychotic activity of drugs 
(Courvoisier, 1956, Arnt, 1982, Wadenberg and Hicks, 1999, Wadenberg et al., 2001). 
With slight experimental modifications, it can be used with rodents as well as with e.g. 
monkeys. The CAR test utilizes the propensity for APDs to reduce responding to a CS 
but has no or little effect on the response to an UCS, in contrast to e.g. sedative drugs, 
where both CS and UCS responding is impaired (Courvoisier, 1956).  
The validity of the model is further supported by the fact that APDs, such as haloperidol 
or olanzapine, are effective in the CAR test at doses that induce similar striatal D2 
receptor occupancy to that observed in patients receiving treatment (Farde et al., 1988a, 
Farde et al., 1992, Wadenberg et al., 2000, Wadenberg et al., 2001). Local injections of 
D2 receptor antagonists into the NAc suppress CAR responding, indicating that D2 
receptor-blockade in this is important for the effect of APDs (Wadenberg et al., 1990). 
The importance of increased dopamine release in the striatum for the symptoms of 
schizophrenia is supported by human imaging studies (c.f. introduction). However, the 
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CAR test is not an indirect measure of striatal D2 receptor occupancy, since the 
suppression of CAR of a low, subeffective, dose of a D2 antagonist, yielding a similar 
D2 occupancy of clozapine in patients, can be potentiated by the addition of e.g. an α2-
adrenoceptor antagonist (Farde and Nordstrom, 1992, Hertel et al., 1999a, Marcus et al., 
2005). In further support of this notion are the results obtained with the muscarinic 
agonist xanomeline, which possess antipsychotic activity (Shekhar et al., 2008) and is 
effective in the CAR test (Shannon et al., 2000). These data indicates that other 
mechanisms of APDs, in addition to D2 receptor occupancy, contribute to the 
antipsychotic-like effect measured in the CAR test, as well as to the clinical effect in 
patients.  
3.3.1. Conditioned avoidance response procedure 
In the present studies, we used a two-way active avoidance test performed in 
conventional shuttle boxes which were divided into two compartments by a partition 
(Salmi et al., 1994b). Upon the presentation of a tone (the CS; 80 dB white noise), the 
rats had 10 s to cross the partition into the other side of the box, or the UCS (i.e. an 
electrical stimuli of approximately 0.3 to 0.4 mA) was delivered. The CAR system was 
automatic and the shuttle box was equipped with photocells connected to a computer to 
continuously monitor the location of the rat, controlling the CS and UCS, and record the 
following behavioral variables; avoidance (respond to CS within 10 s), escape (respond 
to CS+UCS), escape failure (failure to respond to CS and UCS within 60 s). Before the 
start of the experiments, rats were trained for 5 days. Once the rats learn to respond to 
the CS the behavior is very stable, and only rats performing > 85% avoidance were 
included in the study. On experimental days, experiments lasted 10 minutes and were 
preceded by a 10 minute pre-test. The experiments were conducted 20, 90 and 240 min 
(manuscript I) or 5 and 30 min (manuscript II) after injection. Before the start of each 
experimental session the rats were habituated to the box for 5 min. Experimental days 
where always separated by two non-experimental days. All rats received all treatments 
in a counterbalanced change-over design, and thus serving as their own controls (Li, 
1964).  
Data obtained in the CAR experiments are not normally distributed and accordingly, 
non-parametric tests were used. CAR data was analyzed using Friedman’s two-way 
ANOVA using STATISTICA software [Statsoft Inc, USA] followed by Wilcoxon 
matched-pairs signed-ranks test. In all tests, p<0.05 was considered statistically 
significant. 
3.4. Catalepsy  
The measurement of catalepsy in animals is a model with high predictive validity of 
EPS liability in patients (Arnt et al., 1981, Wadenberg, 1996). In rats, catalepsy can be 
defined as “a drug-induced state where the animal, when placed in an awkward or 
unnatural position, will remain in this position for a significantly longer time than 
vehicle-treated control animals” (Wadenberg, 1996). APDs are thought to induce EPS 
and catalepsy by blockade of D2 receptor in the dorsal striatum (Farde et al., 1992, 
Nordstrom et al., 1993, Wadenberg et al., 2001). The level of D2 receptor blockade at 
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which a drug has high risk of catalepsy in rodents and EPS in humans is similar 
(Nordstrom et al., 1993, Wadenberg et al., 2000, Wadenberg et al., 2001). 
Consequently, drugs with high risk of EPS (e.g. haloperidol) induce catalepsy in rodents 
and vice versa, drugs with low risk of EPS in patients (e.g. clozapine and quetiapine) do 
not (Wadenberg et al., 2001, Kapur et al., 2002). Anticholinergic drugs are used to 
ameliorate antipsychotic-induced parkinsonism and can also reverse catalepsy induced 
by D2 receptor antagonists (Arnt, 1982).  
3.4.1. Catalepsy procedure 
The catalepsy experiments in the present studies were performed in a dimly lit room. At 
30, 90 and 120 min after drug administration the rats were placed on an inclining grid 
with an angle of 60°, and, after a 30 s adaptation period, the time to the first paw 
movement was measured. To minimize the risk of bias affecting the scoring, the effect 
of the drug or drug combinations on catalepsy was scored by an observer blind to the 
treatment. 
The recorded time to the first paw movement (in minutes) rendered a score (from 0 to 5) 
according to a scale where the intervals are based on a square root transformation of the 
time: 0.00-0.08 min=0; 0.09-0.35 min=1; 0.36-0.80 min=2; 0.81-1.42 min=3; 1.43-2.24 
min=4: 2.25 min≥5 (Ahlenius and Hillegaart, 1986). A score below 2 indicates low 
propensity to induce catalepsy (Wadenberg et al., 2001). Data from the catalepsy 
measurements are not normally distributed and therefore non-parametric statistical tests 
were used. Catalepsy scores were analyzed by Kruskal-Wallis one-way ANOVA 
followed by Mann-Whitney U-test using STATISTICA software. In all tests, p<0.05 
was considered statistically significant.  
3.5. In vivo microdialysis 
Microdialysis is a technique that allows the continuous measurement of biologic 
molecules such as neurotransmitters from tissues and organs, in living and awake 
animals with minimal tissue damage over long time periods (hours to days; see 
(Ungerstedt and Pycock, 1974, Ungerstedt, 1991). A dialysis probe is implanted in the 
organ of interest and perfused with a perfusion solution, which is collected and can be 
analyzed using conventional analytical methodologies. The semipermeable dialysis 
membrane allows for the diffusion of small (e.g. neurotransmitters) but not large 
molecules (e.g. proteins). Molecules in the extracellular space equilibrate with the 
perfusion solution and the concentration of the molecules of interest in the perfusate 
correlates with the concentration in the surrounding extracellular compartment. 
Microdialysis is widely used in pharmacology and neuroscience to monitor the release 
of neurotransmitters in brain of rodents. In addition to measuring the extracellular 
content of biological molecules, it can also be used to administer substances (e.g. drugs 
or neurotransmitters) directly into the organ of interest with high spatial specificity. The 
samples are collected and analyzed outside the tissue, which allows for the analysis of 
all molecules of interest in each sample and the direct comparison with a known 
standard. 
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However, the microdialysis technique has some important limitations. It is invasive and 
inevitably causes tissue damage in the area around the probe. Therefore, surgical 
implantation must be performed several hours, often days, prior to the experiment. 
Moreover, due to limitations in sensitivity of the method of analysis, the dialysate must 
be collected for some time (up to 30 min in our experiments) to obtain sufficient mass 
of the substance of interest to allow analysis. As a consequence, microdialysis lacks the 
temporal resolution obtained with e.g. biosensors. Therefore, microdialysis is less well 
suited for the measurement of rapid changes in neurotransmitter release. Moreover, 
recovery of molecules from the extracellular space is, in addition to the extracellular 
concentration, dependent on the diffusion over the probe membrane and the diffusion in 
the extracellular space, which may differ between different probes and animals. 
Therefore, in the present studies, we have analyzed changes in neurotransmitter output, 
which then compensates for these technical differences between animals. 
3.6.1. In vivo microdialysis procedure 
In our experiments, rats were anesthetized, placed in a stereotactic frame and surgically 
implanted with a concentric dialysis probe. Dialysis probes were made in-house. The 
probes were implanted in the mPFC and NAc according to the atlas of Paxinos and 
Watson (Paxinos and Watson, 1998) and anchored to the scull with screws and dental 
cement. Rats were allowed 48 h recovery before the start of the experiment. 
Microdialysis experiments were performed in awake, freely moving, rats. During the 
experiments, dialysis probes were perfused with physiological perfusion solution at a 
constant flow rate of 2.5 µl/min and collected for 30 min (mPFC) or 15 min (NAc) for 
analysis.  
After collection, the perfusate was automatically injected on a high performance liquid 
chromatography (HPLC) system. Separation of neurotransmitters and metabolites were 
performed by reversed phase chromatography on a C-18 separation column. Samples 
were analyzed using electrochemical detection in a high-sensitive analytical cell (model 
5111; ESA Bioscience) controlled by a potentiostat with applied potentials of 400 mV 
for detection of metabolites and -200 mV for detection of dopamine, noradrenaline and 
serotonin. Injections of drugs were performed after the output of neurotransmitters and 
metabolites was stable. The correct placement of the probe was verified after the 
experiment in sections of the relevant brain region stained with neutral red. 
Microdialysis data was analyzed using the Totalchrome software (Perkin Elmer, USA) 
which generates both a peak area and peak height for each analyte and sample. The 
obtained retention time and peak area of the sample was compared to that of a known 
standard and the value was expressed as fmol/min. In neither study, did the basal 
concentrations of the analytes differ between the groups in the respective brain area 
(one-way ANOVA), and the data was subsequently expressed as percent of baseline 
(i.e. the mean output of the two [mPFC] or four [NAc] samples preceding the drug 
injection).  
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Statistical evaluation of microdialysis data over time was performed by a repeated 
measures two-way (treatment x time) ANOVA. To analyze the overall effect of the 
different treatments we analyzed the mean neurotransmitter output in studies I and III in 
the interval 60-240 min for mPFC and 45 -240 min for NAc, and in study II in the 
intervals 60-180 min for mPFC and 45 -180 min for NAc . The between groups 
comparison of the overall effect was analyzed using a one-way ANOVA followed by 
planned comparisons of least square means. Effect of treatment was statistically 
evaluated using STATISTICA software. In all tests, p<0.05 was considered statistically 
significant.  
3.6. In vitro electrophysiological recordings  
Hodgkin and Huxley where the first to use intracellular recordings to study electrical 
properties of neurons (Hodgkin and Huxley, 1939). By the late 1940’s Marmont and 
Cole developed a voltage clamp technique, which Hodgkin and Huxley utilized to study 
the mechanisms underlying the generation of action potentials in giant axons of squids 
(see e.g. (Hodgkin et al., 1952). Subsequently, in the 1970’s, Neher and Sakmann 
developed the patch clamp technique, which made it possible to measure conductance 
of single ion channels (see e.g. Neher and Sakmann, 1976). 
The voltage clamp technique allows the experimenter to hold (or clamp) the membrane 
potential of a cell at a fixed value, preventing the activation of voltage dependent ion 
channels which allow recordings or characterizations of activated ligand-gated ion 
channels. In the voltage clamp mode, the ion flow generated by the activation of a 
ligand-gated ion channel is counterbalanced by a current in the opposite direction, 
generated by a voltage-controlled current source, to keep the membrane potential 
steady. The measured current generated by the amplifier is proportional to the current 
generated by the ligand-gated ion channels.  
Electrophysiological recordings of cells in brain slices in vitro have several advantages 
in the study of ion channels. In a slice, electrophysiological measurements are not 
disturbed by fluctuations due to blood flow and breathing of the animal and the content 
of the perfusion solution with regards to e.g. ion concentration as well as drug 
concentrations can be easily manipulated. The placement of the recording electrode is 
also visible to the eye.  
Dopamine release has been shown to occur in rat brain slice preparations e.g. via 
activation of NMDA receptors. This effect was found to be partly TTX insensitive 
(Krebs et al., 1991). Exocytosis of neurotransmitters may occur at a synapse, even 
without presynaptic stimulation, which can be recorded as miniature EPSP. Previous 
studies from our group have shown that depletion of monoamines prevents the 
facilitating effect of a combination of idazoxan and raclopride on NMDA receptor-
mediated synaptic transmission in the slice and that this effect was rescued by L-DOPA 
(Marcus et al., 2005), clearly demonstrating the importance of catecholamines in our 
experiments.  
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3.6.1. Preparation of brain slices 
Rats were decapitated under halothane anesthesia and the brain was cooled in ice-cold 
Ringer’s solution. The brain was cut coronally on a vibratome into 450 µM slices after 
which they kept in aerated Ringer’s solution for >1 h before experiments to allow for 
recovery. A slice containing the mPFC was transferred to the recording chamber (30 
°C) and was held submerged between two nylon nets in aerated Ringer’s solution. The 
chamber was perfused continuously using a gravitational system with a flow-rate of 1-2 
ml/min. Penetration of pyramidal cells in layer V or VI with sharp electrodes was 
performed blindly. Electrodes were manufactured from borosilicate glass capillaries (tip 
resistance of 55-140 MΩ) using a horizontal electrode puller and were filled with 2 M 
potassium acetate.  
3.6.2. Intracellular recordings 
The experiments were recorded using an Axoclamp 2A or 2B amplifier (Molecular 
Devices, USA) connected to a PC running Clampex 9.2 software (Molecular Devices, 
USA), via a digital/analogue interface. Single electrode voltage-clamp recordings were 
performed in the discontinuous mode (sampling rate 5-6.2 kHz) at a holding potential of 
-60 mV. All drugs, as well as NMDA (5-15 µM) and AMPA (2.5- 5 µM), were applied 
by bath perfusion. The effect of NMDA or AMPA induced currents was recorded 
before (control) and after 5 and 30 min of drug application. 
Figure 9. Electrophysiological trace showing injection of 2 
square pulses (1000 ms) of positive current (200 and 300 pA) 
into a presumed pyramidal cell of the rat mPFC, in response 
to which action potentials were elicited. 
 
Presumed pyramidal cells were distinguished from non-pyramidal cells using criteria 
published previously (Connors and Gutnick, 1990, Arvanov and Wang, 1997). 
Presumed pyramidal cells have relatively long spike duration (1-3 ms at half maximum 
spike amplitude) and show a pronounced spike-frequency adaptation in response to 
constant current-depolarization pulses, in contrast to non-pyramidal cells, which have 
relatively short spike duration (< 1 ms at half maximum spike amplitude) and generally 
do not show spike-frequency adaptation. In slice preparations of the PFC four types of 
pyramidal cells can be distinguished by their morphological and corresponding 
electrophysiological properties: the regular spiking, intrinsic bursting, repetitive 
oscillatory bursting and the intermediate type (Yang et al., 1996). 
Excitatory postsynaptic potentials (EPSPs) are transient depolarizations of the cell 
membrane due to the influx of cations via the activation of ligand-gated ion channels. In 
pyramidal cells the EPSP consist of both an early, AMPA-mediated phase, and a 
prolonged, late NMDA-mediated phase (Tanaka and North, 1993, Chen and Yang, 
2002). The opposite, an inhibitory postsynaptic potential (IPSP) is caused by an influx 
of negative ions or outflux of positively charged ions from the cell. IPSPs in pyramidal  
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Figure 10. Micrograph showing a layer V rat pyramidal cell injected 
with biocyntin (Kawaguci 1993). Cortical layers are denoted by 
roman numerals. Layer V-VI pyramidal cells have a triangular (or 
pyramidal) shaped soma with a size averaging approximately 20 µM. 
 
 
 
 
cells of the mPFC are blocked by the GABAA antagonist bicuculline (Chen and Yang, 
2002).The effect of several EPSPs are additive and if the cell membrane is sufficiently 
depolarized over a threshold value, voltage gated ion channels are activated and an 
action potential is elicited. The atypical APD clozapine has been found to induce 
voltage dependent sodium channel-dependent spikes overriding the EPSP. These spikes 
have variable onset latencies and generated by a polysynaptic input to the layer V 
pyramidal cell. However, the action potentials are prevented by NMDA receptor 
antagonists and are thus dependent on NMDA receptor activation (Chen and Yang, 
2002).  
Figure 11. Cartoon illustrating the set-up 
for eliciting and recording EPSPs in 
pyramidal cells of the rat mPFC. Shown are 
the positions of the stimulation electrode and 
the recording electrode. For voltage clamp 
experiments the set-up is similar, but without 
the stimulation electrode. Cg1- Cingulate 
cortex area 1; PrL-Prelimbic cortex; IL-
Infralimbic cortex; fmi-forceps minor; aca-
anterior commissure. Modified from 
(Paxinos and Watson, 1998). 
 
 
 
 
In the present study, electrically evoked EPSPs where achieved by placing two stainless 
steel electrodes in the forceps minor (white matter) proximal to the mPFC and close to 
the recording electrode, in similarity to previously published experiments (figure 11) 
(Arvanov et al., 1997, Chen and Yang, 2002, Jardemark et al., 2012). To elicit EPSPs, 
trains of three square pulses of 0.3 ms (11 to 31 mV) at a rate of 0.05 Hz were passed 
between the tips and the evoked change in membrane potential (i.e. the EPSP) was 
recorded in the current clamp mode in layer V pyramidal cells. The recording electrode 
was filled with 2 M potassium acetate and bicucculine (2µM) was routinely included in 
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the perfusion solution to inhibit GABAA mediated responses. To evaluate the effect of 
drug treatment, a stimulation potential eliciting a sub-maximal response (i.e. EPSP) was 
chosen and the effect was recorded before and after 5, 15, 15 and 35 minutes of drug 
treatment. The effect of drugs or drug-combination was evaluated both qualitatively, for 
their ability to facilitate the induction of action potentials, as well as their effect on the 
total area of the evoked EPSP.  
To investigate whether ketamine pretreatment facilitates NMDA and AMPA receptor-
mediated currents in our slice preparation we injected rats with ketamine (10 mg/kg i.p.) 
or saline (2 ml/kg) 24 h prior to the electrophysiological experiment. Preparation of 
brain slices and recordings of NMDA- (5 µM) and AMPA- (5 µM) induced currents 
were performed as previously described. 
The effect of a drug or drug combination was calculated by dividing the amplitude of 
the AMPA- or NMDA-induced current (in pA) after drug application with the 
amplitude of the control AMPA- or NMDA-induced current. Paired t-test was used to 
evaluate the effect of drug treatment on NMDA- and AMPA-induced currents. 
Unpaired t-test was used to evaluate the effect of ketamine pretreatment on NMDA- and 
AMPA-induced currents. For multiple comparisons, one-way ANOVA followed by 
Tukey HSD (manuscript I) or the Newman-Keuls multiple comparison test (manuscript 
II, III and IV) were used. The areas of the electrically evoked EPSPs were quantified 
using Clampfit 9.2. Due to the large variation of the EPSP area (expressed as mV*ms) 
the data was first log transformed before it was analyzed using a repeated measures 
two-way ANOVA followed Fisher’s Least Significant Difference test. The effect of 
treatment on AMPA- and NMDA-induced currents was statistically evaluated using 
STATISTICA (manuscript I) or Prism (Graphpad Prism Inc., USA; manuscript II, III 
and IV). EPSP data was statistically evaluated using STATISTICA. In all tests, p<0.05 
was considered statistically significant.
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4. Results and discussion 
4.1. Role of concomitant NET-inhibition for the clinical effects of 
antipsychotic drugs 
The prototypical atypical APD clozapine has been found to possess superior efficacy in 
treatment resistant schizophrenia compared to other APDs, even though, or maybe just 
because, clozapine-treatment induces a low striatal D2 receptor occupancy. Clozapine 
has high affinity for the α2-adrenoceptor, which has been suggested to be important for 
its superior efficacy in schizophrenia and allow for its low D2 receptor occupancy. 
However, clozapine treatment is associated with severe side effects, most notably 
agranulocytosis, which limits its use. The atypical APD olanzapine has a structure and 
receptor-biding profile similar to that of clozapine, e.g. higher affinity for several 
serotonergic receptors compared to the D2 receptor, but lacks affinity for the α2-
adrenoceptor. Olanzapine-treatment induces a higher D2 receptor occupancy than 
clozapine and may be associated with side-effects, such as weight gain and EPS, but not 
with agranulocytosis. Interestingly, the antipsychotic-like effect of olanzapine was 
potentiated by addition of the α2-adrenoceptor antagonist idazoxan (Wadenberg et al., 
2007). In similarity to the effects of idazoxan, the NET inhibitor reboxetine has been 
found to enhance dopamine output in the mPFC and to facilitate the antipsychotic-like 
effect of raclopride (Hertel et al., 1999a, Hertel et al., 1999b, Linner et al., 2002), 
indicating that reboxetine may potentially also be used to augment the effect of 
olanzapine.  
In fact, NET inhibition may contribute to the clinical effect of the atypical APD 
quetiapine. Quetiapine exerts its antipsychotic effect in similarity with clozapine, at an 
unusually low D2 receptor occupancy and interestingly, quetiapine treatment has been 
found to generate an active metabolite, norquetiapine, which has high affinity for the 
NET. Norquetiapine has previously been suggested to mediate the antidepressant effect 
of quetiapine (Jensen et al., 2008). However, its contribution to the antipsychotic effect 
of quetiapine has not been investigated. Norquetiapine is not formed in rodents to any 
major extent (Hudzik et al., 2008), making rats a suitable model to study the 
contribution of NET inhibition to the effect of quetiapine. 
4.1.1. Manuscript I 
In the present study, we investigated whether concomitant NET-inhibition potentiates 
the efficacy of the SGA olanzapine and potentially mimic some of the preclinical effects 
of clozapine. We used the CAR test to investigate the effect of concomitant NET-
inhibition on the antipsychotic-like activity of olanzapine and the catalepsy test to 
assess its effect on EPS liability. The effect on dopamine output in the mPFC and NAc 
were assessed using in vivo microdialysis in freely moving rats. Moreover, the effects of 
NET-inhibition combined with olanzapine on cortical NMDA-induced currents using 
intracellular recordings in vitro were also investigated. 
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Figure 12. Concomitant NET-inhibition by reboxetine significantly potentiates the 
antipsychotic-like effect of a sub-optimal (1.25 mg/kg), but not optimal (2.5 mg/kg) dose of 
olanzapine at 20 min after treatment without increasing the EPS liability. (a) The effect on CAR 
behavior at 20 min after administration of vehicle, olanzapine 1.25 or 2.5 mg/kg (i.p.) combined 
with saline or reboxetine (6 mg/kg i.p.). The results are presented as the median avoidance ± 
semi-interquartile range (%).
++
 p<0.01 vs. saline+ vehicle, 
##
 p<0.01 vs. reboxetine+ vehicle, * 
p<0.05 saline + olanzapine vs. reboxetine+olanzapine. (b) All treatments showed very low 
propensity to induce catalepsy. The catalepsy score (60 min after dose) is presented as median 
score ± semi-interquartile range. ++ p< 0.01, +++ p< 0.001 vs. saline+ vehicle. 
Addition of reboxetine (6 mg/kg) to olanzapine potentiated the antipsychotic-like effect 
(i.e. suppression of CAR) of a sub-effective (1.25 mg/kg) but not optimal (2.5 mg/kg) 
dose of olanzapine (figure 12a). Reboxetine (6 mg/kg) as well as olanzapine (2.5 
mg/kg) significantly increased in the catalepsy score (figure 12b). However, the median 
scores were low, below 2 for all treatments, indicating low propensity to induce 
catalepsy. 
 
 
Figure 13. Concomitant NET-inhibition by reboxetine enhances the olanzapine-induced 
dopamine output in the mPFC but not in the NAc. The mean dopamine output in mPFC (a) and 
NAc (b) of vehicle or olanzapine (1.25 mg/kg i.p.) in rats pretreated with saline or reboxetine (6 
mg/kg i.p.). The results are presented as mean ± SEM. 
++
 p<0.01, 
+++
 p< 0.001 vs. control 
group (saline/vehicle); **p<0.01, *** p<0.001 indicate between treatment effects. 
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The enhanced suppression of CAR obtained when reboxetine was added to olanzapine 
was accompanied by a preferential increase in prefrontal dopamine output, without 
affecting the olanzapine-induced dopamine output in the NAc (figure 13 a, b).  
 
 
 
 
 
 
 
Figure 14. Addition of reboxetine to a sub-effective concentration of olanzapine significantly 
enhances the NMDA-induced currents in pyramidal cells of the rat mPFC. Reboxetine (20 nM) 
produced a small but significant increase in the NMDA-induced currents. Addition of 
reboxetine (20 nM) to olanzapine (3 nM) significantly increased these currents compared to 
each drug given alone. 
++
 p<0.01, 
+++
 p<0.001 vs. baseline. *** p< 0.001 between different 
treatments. The results are presented as mean ± SEM. The holding potential was -60 mV. 
Addition of reboxetine to a sub-effective concentration of olanzapine enhanced NMDA-
induced currents in pyramidal cells from the rat mPFC (figure 14). 
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4.1.2. Manuscript II  
In the present study, we used reboxetine as a model compound due to its high 
specificity for the NET, to investigate in principle, whether NET-inhibition, obtained in 
patients by the active metabolite norquetiapine, contributes to the antipsychotic effect of 
quetiapine. 
The effect of concomitant NET-inhibition on the antipsychotic-like effect of quetiapine 
was studied using the CAR model. The effect on dopamine and DOPAC output was 
assessed using microdialysis and the effect on NMDA-induced currents was studied 
using in vitro intracellular recordings. In addition, we investigated the effects of adding 
reboxetine to the selective D2/3 receptor antagonist raclopride on cortical NMDA-
induced currents. 
 
Figure 15. Addition of reboxetine to quetiapine potentiates the quetiapine-induced suppression 
of conditioned avoidance behavior. (a) The effect of quetiapine (1, 3, 6 and 9 mg/kg i.v.; n=12) 
on CAR behavior. (b) The effect of quetiapine alone and after pretreatment with reboxetine (6 
mg/kg; n=11) . The results are presented as median avoidance (%) ± semi-interquartile range. 
*p<0.05, **p<0.01, *** p<0.001 vs. vehicle, 
#
 p< 0.05 as indicated in the figure.  
 
Quetiapine, given i.v., produced a short-lasting suppression of the CAR behavior at 6 
and 9 mg/kg (figure 15a). Pretreatment with reboxetine (6 mg/kg i.p.) produced a small 
but significant potentiation of the antipsychotic-like effect of quetiapine at 3 mg/kg 
(figure 15b). Reboxetine pretreatment seemed to facilitate the suppression of CAR 
behavior also of the higher dose of quetiapine (6 mg/kg) but this effect did not reach 
statistical significance.  
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Figure 16. Addition of reboxetine to quetiapine enhances the dopamine output in the mPFC but 
not in the NAc. Effects of quetiapine (6mg/kg i.v.) and reboxetine (6 mg/kg i.p.) on dopamine (a, 
b) and DOPAC (c, d) output in the mPFC and NAc respectively. The results are presented as 
mean ± SEM. **p< 0.01, ***p<0.001 vs. control group (i.e. saline+vehicle).
 #
p<0.05, 
##
p<0.01, 
###
p<0.001 comparisons as indicated in the figure.  
Addition of reboxetine to quetiapine induced a large increase in the dopamine output in 
the mPFC but not in the NAc (figure 16 a, c). The increased cortical dopamine output 
was accompanied by a reduction in the DOPAC output (16 b). 
Quetiapine facilitated NMDA-induced currents (figure 17b), in similarity to previously 
published results (Ninan et al., 2003b). Addition of reboxetine to a sub-effective 
concentration of quetiapine enhanced the NMDA-induced currents compared to each 
drug when given alone (figure 17c). The facilitatory effect was prevented by the 
addition of the dopamine D1 receptor antagonist SCH23390. Addition of reboxetine to 
raclopride also increased the NMDA-induced currents compared to each drug given 
alone (figure 17d). 
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Figure 17. Concomitant NET-inhibition potentiates the effect of quetiapine and raclopride on 
NMDA-induced responses compared to each drug given alone in pyramidal cells of the rat 
mPFC. (a) Representative electrophysiological traces illustrating the effect of combined 
quetiapine and reboxetine on the NMDA-induced currents in pyramidal cells of the mPFC. (b) 
concentration-response curve of the effect of quetiapine on NMDA-induced currents. (c) The 
effect on NMDA-induced currents of a sub-effective concentration of quetiapine (60 nM), 
reboxetine (20 nM), the combination of quetiapine and reboxetine, and the effect of quetiapine 
and reboxetine in the presence of the dopamine D1 receptor antagonist SCH23390. (d) The 
effect of reboxetine (20 nM), the D2/3 receptor antagonist raclopride (1 µM) and the 
combination of reboxetine (20 nM) and raclopride (1µM) on NMDA-induced currents. The 
results are presented as mean ± SEM. *p<0.05 compared to baseline. #p<0.05, ##p<0.01, 
between groups comparison as indicated in the figure.  
4.1.3. Discussion: Role of concomitant NET-inhibition for the clinical effects of 
antipsychotic drugs 
Addition of reboxetine potentiated the antipsychotic-like effect of a sub-effective dose 
of olanzapine, without inducing catalepsy, indicating that adjunctive treatment with 
reboxetine may allow for a dose reduction of olanzapine with maintained antipsychotic 
effect. In similarity, addition of reboxetine also potentiated the antipsychotic-like effect 
of quetiapine, which suggests, in principle, that NET-inhibition provided in patients by 
the metabolite norquetiapine, contributes to the antipsychotic effect of quetiapine, 
which is obtained despite its relatively low D2 receptor occupancy. These results are in 
similarity to previous studies from our group investigating addition of a NET-inhibitor 
and an α2-adrenoceptor antagonist to low doses of a D2/3 receptor antagonist (Hertel et 
al., 1999a, Linner et al., 2002). 
Addition of reboxetine to both olanzapine and quetiapine preferentially enhanced the 
dopamine output in the mPFC, without affecting the dopamine output in the NAc. In 
parallel, the DOPAC output in the mPFC was decreased when reboxetine was added to 
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quetiapine. A reduction of the intracellularly derived metabolite DOPAC in the mPFC 
when reboxetine is added to quetiapine indicates that the enhanced dopamine output 
may stem from an enhanced dopamine turnover generated by an increased VTA cell 
firing induced by the APD (Gessa et al., 2000, Yamamura et al., 2009). The enhanced 
turnover is not observed as increased dopamine output when the APD is given alone, as 
the released dopamine can be cleared from the extracellular space by the NET. 
Reboxetine, by blocking the NET, thus unmasks the enhanced turnover. Another 
contributing mechanism may be blockade of D2 autoreceptors by olanzapine and 
quetiapine, disinhibiting dopamine outflow (Westerink et al., 2001). 
Concomitant NET-inhibition facilitated the NMDA-induced currents of olanzapine, 
quetiapine and raclopride compared to either drug given alone. The effect of the 
reboxetine/quetiapine combination was mediated via D1 receptor activation similar to 
what has been demonstrated in previous studies (Chen and Yang, 2002, Ninan and 
Wang, 2003, Marcus et al., 2005). Given the crucial importance of D1 and NMDA 
receptor mediated transmission for cognitive function and the observed cognitive 
deficits in schizophrenia these results, indicate that APD-treatment with concomitant 
NET-inhibition, may, by facilitation of dopaminergic and NMDA receptor-mediated 
transmission, serve to ameliorate cognitive deficits as well as both depressive and 
negative symptoms in schizophrenia, and may thus be an underlying mechanism 
contributing to the pro-cognitive effect of quetiapine treatment obtained in 
schizophrenia (c.f. 1.8.2). 
The increased cortical dopamine output may also contribute to the enhanced 
antipsychotic-like effect per se, since dopamine acting on D1 receptors in the mPFC has 
been found to suppress subcortically derived D2 receptor-mediated behaviors (c.f. 
1.8.2). 
Previous clinical studies investigating adjunctive treatment with reboxetine to APD 
treatment in schizophrenia yielded both positive and negative results (Schutz and Berk, 
2001, Raedler et al., 2004). However, present data indicates that one of the potential 
benefits of concomitant NET-inhibition would be obtained at reduced dosage of APD 
rather than at standard doses of APDs. A dose-reduction of olanzapine enabled by 
addition of reboxetine, with ensuing reduced D2 receptor occupancy, or norquetiapine in 
quetiapine-treated patients, may not only reduce the risk of side-effects (e.g. EPS) 
(Kapur et al., 2000), but also reduce the risk of drug-induced negative symptoms, 
cognitive deficits, negative mood and impaired reward prediction associated with high 
D2 receptor occupancy (Carpenter, 1996, Saeedi et al., 2006, Kirsch et al., 2007). 
Moreover, previous studies have suggested that enhanced cortical catecholamine output 
may underlie the beneficial effects of addition of atypical APDs to SSRIs in treatment-
resistant MDD and bipolar depression (c.f. 1.11.2). Therefore, the marked facilitation of 
prefrontal dopamine output observed in the present studies thus proposes that NET-
inhibition, in combination with the properties of an atypical APD, may contribute to 
relieve depressive symptoms.  
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4.2. Effects of low doses of atypical antipsychotic drugs added to SSRIs 
on monoaminergic and glutamatergic neurotransmission in the mPFC. 
Addition of low to moderate doses of atypical APDs has been found to potentiate the 
antidepressant effect of antidepressants in both bipolar depression as well as in 
treatment-resistant MDD, with a rapid onset of the effect (see e.g. Dube et al., 2007, 
Nelson and Papakostas, 2009). Previous preclinical studies, investigating addition of the 
atypical APD olanzapine to the SSRI fluoxetine, have suggested that this effect may, at 
least partly, be due to the increased catecholamine output in the mPFC (Zhang et al., 
2000). Moreover, addition of low, sub-effective concentrations of APDs to SSRIs has 
also been found to facilitate NMDA receptor-mediated transmission in pyramidal cells 
of the rat mPFC (Marcus et al., 2012). Preclinical studies investigating the mechanism 
of action of ketamine and scopolamine, show that the antidepressant-like effect is 
critically dependent on activation of AMPA receptors, and subsequently, on 
intracellular mechanisms involving the mammalian target of rapamycin (mTOR) 
pathway in the mPFC (Maeng et al., 2008, Li et al., 2010, Voleti et al., 2013, but see 
also Autry et al., 2011). Ketamine and scopolamine treatment was found to induce 
synapse formation and to increase e.g. the number of AMPA receptor GluR1 subunits in 
the synapses and to increase glutamatergic transmission in pyramidal cells of the rat 
mPFC (Li et al., 2010).  
4.2.1. Manuscript III 
Asenapine is a novel APD used in bipolar disorder and in the present study we 
investigated the potential utility of asenapine as an adjunct to the SSRI escitalopram. 
The effects of add-on of low doses of asenapine to escitalopram on dopamine, 
noradrenaline and serotonin output in the mPFC and dopamine output in the NAc were 
investigated using in vivo microdialysis in freely moving rats. Furthermore, we 
investigated the effects of the drug combination on NMDA and AMPA receptor-
mediated currents as well as the effect on electrically evoked excitatory post-synaptic 
potentials (EPSPs) using intracellular recordings of pyramidal cells in vitro. 
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Figure 18. Addition of asenapine to escitalopram enhances dopamine output in the mPFC. 
Effects of escitalopram (5 mg/kg s.c.), asenapine (0.05 mg/kg s.c.), given alone and in 
combination on the mean output of dopamine (a), noradrenaline (b) and serotonin (c) in the 
mPFC and mean dopamine output in the NAc (d). The dotted line represents baseline (100 %). 
The results are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 vs. control (i.e. 
saline + saline). 
#
p<0.05, 
###
p<0.001 between groups comparison as indicated in the figure. 
Asenapine (0.05 mg/kg) increased the dopamine output in the mPFC, an effect that was 
further enhanced when asenapine was combined with escitalopram (5 mg/kg; figure 
18a). Both escitalopram and asenapine increased dopamine output in the NAc, but there 
was no further increase when the two drugs were combined (figure 18d). Asenapine 
(0.05 mg/kg) increased the noradrenaline output (figure 18b) and escitalopram increased 
the serotonin output (figure 18c) in the mPFC. However, the output of these 
monoamines was not further increased when the two drugs were combined.  
                                                                                                                                      Results and discussion 
49 
 
 
Figure 19. Addition of a higher dose of asenapine to escitalopram increases noradrenaline and 
serotonin output in the mPFC. Effects of escitalopram (5 mg/kg s.c.), asenapine (0.1 mg/kg s.c.), 
given alone and in combination on the mean output of dopamine (a), noradrenaline (b) and 
serotonin (c) in the mPFC and mean dopamine output in the NAc (d). The dotted line represents 
baseline (100 %) The results are presented as mean ±SEM. *p<0.05, **p<0.01, ***p<0.001 vs. 
control (i.e. saline + saline). 
##
p<0.01, 
###
p<0.001 between groups comparison as indicated in 
the figure.  
A higher dose of asenapine (0.1 mg/kg) enhanced the dopamine output in the mPFC but 
in contrast to the effect of the lower dose of asenapine (0.05 mg/kg), the effect was not 
further increased when combined with escitalopram (figure 19a). Asenapine also 
increased the dopamine output in the NAc but in similarity to the effect of the lower 
dose of asenapine in the NAc, this effect was not affected by concomitant escitalopram 
treatment (figure 19d). Asenapine (0.1 mg/kg) did not increase noradrenaline or 
serotonin output when given alone, however when combined with escitalopram the 
combination induced a large increase in noradrenaline (figure 19b) as well as serotonin 
output (figure 19c).  
The combination of low, sub-effective, concentrations of asenapine (1 nM) and 
escitalopram (3 nM) significantly enhanced NMDA-induced currents in pyramidal cells 
of the rat mPFC via activation of the dopamine D1 receptor (figure 20f) in similarity 
results obtained when asenapine and escitalopram was investigated separately 
(Jardemark et al., 2010, Schilström et al., 2011).  
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Figure 20. A combination of asenapine and escitalopram facilitates NMDA-induced currents 
via activation of the dopamine D1 receptor. Representative electrophysiological traces showing 
the effect of NMDA application before (grey trace) and after (black trace) application of (a) 
escitalopram 3 nM (b) asenapine 1 nM (c) asenapine+ escitalopram (d) asenapine+ 
escitalopram + SCH23390 (1 µM). The grey and black horizontal bars indicate the time of 
NMDA application for control and test trace, respectively. Data is summarized in bar charts 5 
min (e) and 30 min (f) after drug application. The results are presented as mean ±SEM. 
*p<0.05 vs. control response, 
##
p<0.01 between groups comparison as indicated in the figure. 
 
 
Figure 21. Concentration-response curves for asenapine and escitalopram of AMPA-induced 
currents at 5 min (a) and 30 min (b) after drug application. Data are presented as mean ± SEM. 
The holding potential was -60 mV. 
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A combination of asenapine (1 nM) and escitalopram (3 nM) also facilitated AMPA-
induced currents (figure 22 e, f), an effect that was not attainable by either drug when 
administered alone, even at higher concentrations (21 a, b). The facilitation of AMPA-
induced currents was antagonized by SCH23390 (1µM). Moreover, the combination of 
asenapine (1 nM) and escitalopram (3 nM) induced action potentials in all four cells 
tested and increased the total area of the electrically evoked EPSPs (figure 23 a to d).  
 
 
Figure 22. A combination of asenapine and escitalopram facilitates AMPA-induced currents 
via activation of the dopamine D1 receptor. Representative electrophysiological traces showing 
the effect of AMPA application before (grey trace) and after (black trace) application of (a) 
escitalopram 3 nM (b) asenapine 1 nM (c) asenapine+ escitalopram (d) asenapine+ 
escitalopram + SCH23390 (1 µM). The grey and black horizontal bars indicate the time of 
AMPA application for control and test trace, respectively. Data is summarized in bar charts 5 
min (e) and 30 min (f) after drug application. The results are presented as mean ±SEM. 
*p<0.05, **p<0.01 vs. control response, 
#
p<0.05, 
##
p<0.01, 
###
p<0.001 between groups 
comparison as indicated in the figure. 
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Figure 23. A combination of asenapine and escitalopram induces action potentials and 
increases the area of the electrically evoked EPSPs in pyramidal cells of the rat mPFC. 
Representative electrophysiological traces showing the electrically evoked EPSPs before (grey) 
and after (black) treatment with (a) escitalopram 3 nM (b) asenapine 1 nM and (c) escitalopram 
3 nM+ asenapine 1 nM. Arrows indicate time of stimulation. The logarithm of the mean EPSP 
area (log10 mV*ms) is summarized in (d). Asenapine+ escitalopram enhanced the EPSP area 
compared to both escitalopram (**p<0.01, ***p<0.001), asenapine (
##
p<0.01) as well as its 
own control EPSP area (i.e. the EPSP area before drug application; 
¤¤¤
p<0.001). The results 
are presented as mean ± SEM. 
 
4.3.2. Manuscript IV 
Given the similarities in the clinical outcome between the olanzapine and fluoxetine 
combination and ketamine treatment (i.e. potent antidepressant action and relatively 
rapid onset of the effect) we investigated the effect of combined olanzapine and 
fluoxetine on NMDA and AMPA receptor- mediated transmission using intracellular 
recordings in in vitro slice preparations. The combination of olanzapine and fluoxetine 
has previously been found to increase dopamine output in the mPFC, and therefore we 
also investigated whether an effect on this drug combination on NMDA and AMPA 
receptor-mediated transmission was dependent on D1 receptor activation. Moreover, to 
allow for a comparison with ketamine, the effect of a single injection of ketamine on the 
NMDA- and AMPA–induced currents in pyramidal cells was investigated in prefrontal 
brain slices 24 hours after the time of ketamine injection, by using intracellular 
recordings. 
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Figure 24. A combination of olanzapine (3 nM) and fluoxetine (100 nM) facilitates NMDA-
induced currents in pyramidal cells of the rat mPFC via activation of the dopamine D1 receptor. 
Bar charts show the effect on NMDA-induced currents of fluoxetine (100 nM), olanzapine 
(3nM), fluoxetine (100 nM) + olanzapine (3 nM) and fluoxetine (100 nM) + olanzapine (3nM)+ 
SCH23390 (1µM) at (a) 5 min and (b) 30 min of drug administration. Data are presented as 
mean ± SEM (%). *p< 0.05 compared to control response. 
#
p<0.05, 
##
p<0.01 indicates a 
between groups effect, as indicated in the figure. The number in each bar shows group size.  
 
The combination of olanzapine and fluoxetine potentiated NMDA-induced currents in 
pyramidal cells of the rat mPFC (figure 24), an effect that was mediated via D1 receptor 
activation as it was blocked by SCH23390. Interestingly, the combination of olanzapine 
and fluoxetine facilitated AMPA receptor-mediated currents (figure 25) even though 
neither drug had any effect when given alone. The facilitation of AMPA-induced 
currents was prevented by pretreatment with a D1 receptor antagonist, indicating that D1 
activation was necessary for this effect. 
 
Figure 25. A combination of olanzapine and fluoxetine facilitates AMPA-induced currents in 
pyramidal cells of the rat mPFC, via activation of the dopamine D1 receptor. Bar charts 
showing the effect on AMPA-induced currents at (a) 5 min and (b) 30 min of drug 
administration. Data are presented as mean ± SEM (%). *p< 0.05 compared to control 
response. 
#
p<0.05 indicates a between groups effect, as indicated in the figure.  
There was a trend for ketamine pretreatment towards enhancing the NMDA-induced (5 µM) 
currents, although this effect failed to reach statistical significance (figure 26a; p=0.0576). 
However, ketamine pretreatment significantly facilitated AMPA-induced (5 µM) currents 
(figure 26b). 
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Figure 26. Ketamine pretreatment enhanced AMPA-induced currents in pyramidal cells of the 
rat mPFC. (a) NMDA-induced currents in pyramidal cells from rats pretreated with ketamine 
(10 mg/kg) or saline (2 ml/kg). Bar chart shows mean± SEM. There was a trend for ketamine 
pretreatment to enhance the NMDA-induced currents but it failed to reach statistical 
significance (p=0.0576). (b) Ketamine pretreatment significantly enhanced AMPA-induced 
currents in pyramidal cells of the mPFC. *p<0.05 ketamine compared to saline. The number in 
each bar shows the groups size. The holding potential was -60 mV.  
4.3.3. Discussion: Effects of low doses of atypical antipsychotic drugs added to SSRIs 
on monoaminergic and glutamatergic neurotransmission in the mPFC. 
Addition of low doses of asenapine to escitalopram enhanced the outflow of dopamine, 
noradrenaline and serotonin in the mPFC, indicating that asenapine may be effective as 
an adjunct in treatment-resistant depression, in similarity with e.g. olanzapine or 
quetiapine (c.f. 1.11.2). Asenapine is an antagonist at 5-HT2A, α2 and D2 receptor and a 
partial agonist at the 5-HT1A receptor, all of which may contribute to the increased 
monoamine release obtained when combined with the SSRI escitalopram. The increased 
monoamine outflow induced by this drug combination may stem from both systemic 
effects (Arborelius et al., 1993, Szabo and Blier, 2002, Ghanbari et al., 2009) as well as 
local mechanisms within the mPFC (Franberg et al., 2012). Clinical and preclinical 
studies suggest that α2 and 5-HT2A receptor antagonists can be used to potentiate the 
antidepressant or antidepressant-like effect of SSRIs (see e.g. Sanacora et al., 2004, 
Marek et al., 2005), further supporting the utility of asenapine as adjunct in MDD. 
Using intracellular recordings in brain slices, we found that combinations of asenapine 
and escitalopram as well as of olanzapine and fluoxetine facilitated both NMDA and 
AMPA receptor-mediated transmission in the mPFC, via activation of the dopamine D1 
receptor. In similarity, injection of ketamine 24 hours prior to the electrophysiological 
experiment also produced a facilitation of AMPA receptor-mediated transmission, 
compared to saline treated rats. Moreover, ketamine pretreatment appeared to enhance 
also NMDA receptor-mediated transmission, although this effect did not reach 
statistical significance. Previous studies in rats have found ketamine pretreatment to 
enhance a number of synaptic proteins including the AMPA receptor subunit GluR1 and 
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to facilitate glutamatergic transmission in the mPFC and that the antidepressant-like 
effect of ketamine was abolished by a selective AMPA receptor antagonist (c.f. 1.11.1). 
Thus, the seemingly analogous results obtained with a combination of an atypical APD 
and an SSRI compared to the effect of ketamine in the present study, indicates that also 
the relatively rapid onset of the antidepressant effect obtained with a combination of 
atypical APDs and antidepressant drugs may be related to an enhancement of cortical 
AMPA receptor-mediated transmission. Further support for the notion that AMPA 
receptor-activation induces an antidepressant response is provided by studies showing 
that AMPA receptor allosteric modulators may exert a rapid antidepressant effect in 
animal models predictive of antidepressant effect (Li et al., 2001, Knapp et al., 
2002).The mechanism by which the combinations of atypical APDs and SSRIs facilitate 
AMPA receptor-mediated transmission is not entirely clear. Although previous 
electrophysiological studies investigating the influence of D1 activation on AMPA 
receptor-mediated transmission have generated conflicting results (see e.g. Tseng and 
O'Donnell, 2004, Smith et al., 2005), D1 receptor activation has been found to increase 
and D2 receptor activation to decrease the number of AMPA receptors on the cell 
surface of cortical pyramidal cells (Sun et al., 2005). Thus, enhanced dopamine outflow 
with concomitant blockade of the D2 receptor, produced by the APD and SSRI, results 
in a preferential activation of D1 receptors, which may result in an increase of the 
number of cell surface AMPA receptors. However, other mechanisms (e.g. serotonergic 
mechanisms) probably contributes to the facilitation of AMPA receptor-mediated 
transmission, since neither clozapine nor asenapine facilitates these currents when given 
alone, even though they facilitate NMDA receptor-mediated currents via the activation 
of the D1 receptor at the same concentration (Arvanov et al., 1997, Jardemark et al., 
2010). Tentatively, in the intact animal, ketamine may also, by augmenting the AMPA 
receptor-mediated transmission, secondarily enhance NMDA receptor-mediated 
transmission by reducing the voltage dependent Mg
2+
-blockade.  
Moreover, since the effect of ketamine seemed to be relatively more pronounced on 
AMPA receptor-mediated currents than on NMDA induced currents, our data are in 
principle consonant with previous findings and conclusions regarding the mechanism of 
action of ketamine (Maeng and Zarate, 2007). 
Asenapine and escitalopram as well as a combination of olanzapine and fluoxetine 
facilitated NMDA receptor-mediated transmission via D1 receptor activation. We also 
found that a combination of asenapine and escitalopram enhanced the area of the EPSPs 
and induced bursts of action potentials overriding the EPSPs in pyramidal cells of the 
rat mPFC, in similarity with results previously obtained with clozapine (Chen and 
Yang, 2002, Jardemark et al., 2005). This effect of clozapine was found to be dependent 
on NMDA and D1 receptor activation. The action potentials induced by a combination 
of asenapine and escitalopram had varying onset latencies, indicating that they were 
elicited by recurrent activation of neighboring layer V pyramidal cells. This recurrent 
excitation of pyramidal cells in the PFC is thought to some extent explain the 
underlying physiological mechanism for working memory. Thus, low doses of 
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asenapine in combination with an SSRI may contribute to relieve cognitive deficits in 
e.g. depression. In addition to effects on memory, the activity of the NMDA receptor 
may also play a role in the antidepressant response per se, since drugs mediating their 
effect via the co-agonist site of the NMDA receptor (e.g. D-serine and a glycine 
reuptake inhibitors) have been found to generate an antidepressant effect in patients as 
well as in animal models predictive of antidepressant activity (Malkesman et al., 2012, 
Huang et al., 2013). 
Ketamine, and other NMDA receptor-antagonists, has previously been found to increase 
dopamine release in the mPFC and D1 receptor stimulation has been found to stimulate 
the mTOR pathway in the cortex (Schicknick et al., 2008). However, to which extent 
increased outflow in the mPFC induced by a combination of atypical APDs and an 
SSRI affect mTOR signaling, and to which extent dopamine-related effects of ketamine 
may contribute to its antidepressant effect remain to be determined. 
In conclusion, we propose that the relatively rapid and enhanced antidepressant effect 
obtained when low to moderate doses of atypical APDs are added to SSRIs may result 
from a facilitation of monoamine outflow with ensuing facilitation of glutamatergic 
transmission in the PFC.
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5. Summary and concluding remarks 
Although considered as two separate diagnostical entities, increasing evidence points to 
a link between schizophrenia and depression. For example, depression is a common 
prodromal symptom of schizophrenia and it is estimated that the life-time prevalence of 
comorbid depression is 50% in schizophrenia and, vice versa, psychotic symptoms are 
more prevalent in patients diagnosed with depression as compared to the general public 
(Buckley et al., 2009). Depressive symptoms in schizophrenia are associated with 
poorer quality of life and worse long-term outcomes (Conley et al., 2007). The link 
between schizophrenia and depression is further supported by a recent study which 
showed that schizophrenia not only has a shared heritability with bipolar disorder (c.f. 
1.9.1) but also with depression (Lee et al., 2013). 
Moreover, the use of low doses of atypical APDs in non-psychotic depressed patients 
has been steadily increasing over the last decade. Results from a recent European study 
show that approximately 50% of the depressed in-patients in the study received an APD 
(Kasper, S., personal communication). Interestingly, the study also concluded that 
psychiatrists prescribed atypical APDs at moderate dosage as adjunct treatment to 
depressed patients to augment the antidepressant effect even long before regulatory 
authorities approved APDs for this indication. 
In the present set of experimental studies we demonstrated that addition of the NET 
inhibitor reboxetine may further enhance the antipsychotic-like effect of a low but not a 
high dose of olanzapine, without increasing EPS liability. In parallel, adjunct reboxetine 
preferentially enhanced olanzapine-induced cortical dopamine output and facilitated 
NMDA receptor-mediated transmission in the mPFC. Similar results were obtained in a 
subsequent study when quetiapine was combined with the NET-inhibitor reboxetine. 
Moreover, we found that low doses of the novel atypical APD asenapine in combination 
with escitalopram enhanced monoamine output in the mPFC, and to some extent 
dopamine output in the NAc. Using electrophysiological intracellular recordings we 
found that a combination of low, clinically relevant concentrations of asenapine and 
escitalopram increased the area of electrically evoked EPSPs and facilitated the 
generation of action potentials in pyramidal cells of the rat mPFC.  
Our data propose that concomitant NET-inhibition may allow for a lower D2 receptor 
occupancy induced by the APD, yet with maintained antipsychotic effect. Concomitant 
NET inhibition may also ameliorate depressive and negative symptoms as well as 
cognitive impairments in schizophrenia by facilitating cortical dopaminergic 
transmission as well as NMDA receptor-mediated transmission. Moreover, our data 
propose that addition of reboxetine to olanzapine may allow for a dose reduction of 
olanzapine with maintained antipsychotic effect and an ensuing reduced risk of 
extrapyramidal side effects. Our data also suggest that NET inhibition, generated in 
patients by the active metabolite norquetiapine, may not only contribute to the 
antidepressant effect of quetiapine but, in addition, to the antipsychotic effect of 
quetiapine, that can be obtained in patients in spite of a low D2 receptor occupancy. 
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We also showed that addition of asenapine to the SSRI escitalopram enhanced 
catecholamine output in the mPFC, in similarity with results obtained with olanzapine 
and fluoxetine (Zhang et al., 2000). In addition to the increased catecholamine output 
the combination of asenapine and escitalopram also facilitated serotonin output in the 
same brain region, in contrast to the effects obtained with olanzapine added to 
fluoxetine. This difference may be explained by the α2-adrenoceptor antagonistic and 5-
HT1A partial agonistic properties of asenapine (Ghanbari et al., 2009, Franberg et al., 
2012), receptors to which olanzapine have very low affinity (Schotte et al., 1996). This 
effect may be important, since an enhanced serotonin output may confer a therapeutic 
advantage in depression. 
Asenapine and escitalopram as well as a combination of olanzapine and fluoxetine 
significantly potentiated NMDA receptor-mediated transmission via D1 receptor 
activation in pyramidal cells in vitro, in similarity with the effects of clozapine. Given 
the importance of D1 and NMDA receptor-mediated transmission in the mPFC for 
optimal cognitive function, this effect may contribute to ameliorate several aspects of 
cognitive dysfunctions in both schizophrenia and depression. 
In subsequent electrophysiological experiments we showed that a combination of 
asenapine and escitalopram, as well as a combination of olanzapine and fluoxetine at 
low, clinically relevant concentrations, facilitates AMPA receptor-mediated 
transmission in pyramidal cells of the rat mPFC. Our data suggest that activation of the 
D1 receptor may be necessary but probably not sufficient to facilitate AMPA receptor-
mediated transmission. This effect was thus obtained by two different combinations of 
atypical APDs and SSRIs, proposing that facilitation of AMPA receptor-mediated 
transmission may represent a general effect of such drug combinations, in parallel with 
the enhanced antidepressant effect, which has been observed clinically with atypical 
APDs used as adjunct to SSRIs (Nelson and Papakostas, 2009). In support of this 
contention, our data demonstrate an enhanced AMPA receptor-mediated transmission in 
the mPFC following administration of a single dose of ketamine, 24 hours before (c.f. 
(Li et al., 2010), which has been found to generate a powerful antidepressant action with 
a fast onset of action.  
In summary, our results propose that the rapidly augmented antidepressant effect 
obtained by adjunct treatment with low doses of atypical APDs in treatment-resistant 
depression maintained on conventional antidepressant drugs may be related to 
facilitation of monoamine outflow in the PFC with an associated facilitation of 
glutamatergic transmission. 
Moreover, our results propose that asenapine may have potential clinical utility as 
adjunct treatment in treatment-resistant major depression, generating an enhanced 
antidepressant effect with a rapid onset. In fact, a clinical study investigating asenapine 
as adjunct to antidepressant drugs is currently ongoing (ClinicalTrials.gov Identifier: 
NCT01670019). 
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